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REACTION PROFILE OF ANTIDIABETIC DRUGS IN PATIENTS 
ATTENDING A TEACHING HOSPITAL 
 
Shanthi M1, Rema Menon N2, Kaniraj Peter. J3, Madhavrao C4 
1Postgraduate, 2Professor and Head, 4Assistant Professor  
Department of Pharmacology  
3Professor and Head,  
Department of Medicine  
SMIMS, Kulasekharam, Kanyakumari, Tamil Nadu 
 
Aims and objectives: 
To study the utilization pattern, rationality, prescription by brand name 
or generic name, adverse drug reaction profile and pharmacoeconomic 
analysis of antidiabetic drugs      
   
Materials and Methods:  
A cross-sectional study was done for a period of one year (between 
August 2013 to August 2014) at outpatient department of Medicine, Sree 
Mookambika Institute of Medical Sciences, Kulasekharam, Kanyakumari 
District, Tamil Nadu.  
 
Results:  
169 prescriptions were evaluated during the study period. DM was 
predominant among the female population in this region. Demographic details 
of the patient included in the study were mean weight 67.56 kg, mean height 
155 cm and average body mass index 27.82 kg/m2. All the patients were 
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diagnosed as type 2 DM and majority being known case of DM. Systemic 
hypertension was the frequently encountered co-morbid conditions associated 
with DM. Metformin was the drug chosen for managing DM as monotherapy. 
73% of the patients were on combination of antidiabetic drugs. Glimepiride 
with metformin was the two drug combination therapy frequently prescribed 
during the study period. Adverse drug reactions reported during the study 
were hypoglycemia, gastrointestinal discomfort, edema, rashes and myalgia. 
Majority of ADRs assessed were probable by WHO scale and possible by 
Naranjo scale. Modified Schumock and Thornton scale assessed many ADRs 
to be not preventable. As per the modified Hartwig and Siegel scale none of 
the ADRs were severe. Pharmacoeconomic analysis identified that drugs 
prescribed by brand name were costlier compared to generic equivalent. 
Various antidiabetic drugs were prescribed during the study period in which 
least expensive was glibenclamide and most expensive was sitagliptin. 
 
Conclusion:  
Utilization of antidiabetic therapy in this region has shown a changing 
trend compared to the previous studies. There is a gradual increase in the 
prescription of metformin and dramatic increase in the use of newer drugs like 
pioglitazone, voglibose and sitagliptin. Adverse effect more noted in our study 
was hypoglycemia. Glibenclamide was the least expensive while sitagliptin 
was the most expensive in this study.    
2 | P a g e  
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1. Introduction: 
Diabetes mellitus (DM) is a metabolic disorder characterized by 
hyperglycemia due to absolute or relative deficiency of insulin.1 This non 
communicable disease is an emerging epidemic and India topped the world in 
2007 with 31.7 million population affected with DM.2 Prevalence of DM is 
progressing rapidly worldwide. Currently 285 million are affected by diabetes 
globally.3 In India, 62 million are diagnosed to be diabetic and is estimated to 
reach 79.4 million by 2030.1 Study on global prevalence of DM predicted that 
the annual growth will be 2.2% which is double the growth of adult 
population.4 Prevalence of DM in Tamil Nadu was found to be 10.4% in a 
study done by Anjana et al.5   
DM has a major impact on life style of the affected population. Food 
plays an important role in the development of this metabolic disorder along 
with genetic and environmental factors. Insulin is a polypeptide hormone 
secreted by β islets of Langerhans in the pancreas. It is an anabolic hormone 
which will increase the storage of glucose and help in the conversion of 
glucose to fat and proteins. Hyperglycemia, the cardinal feature of DM 
develops due to reduced insulin secretion or reduced glucose utilization.1,6,7  
Manifestations of hyperglycemia are polyuria, polydypsia, polyphagia 
and weight loss. Acute life threatening consequence of uncontrolled DM is 
diabetic ketoacidosis and hyperglycemic hyperosmolar state. Multiple organs 
undergo secondary patho physiological changes due to this altered 
metabolism. Majority of end-stage renal disease (ESRD), nontraumatic lower 
extremity amputations, and adult blindness are complications due to DM. 1,6,7 1 | P a g e  
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Management of DM require both non pharmacological and 
pharmacological interventions. Parenteral Insulin preparation and oral 
hypoglycemic medication are the currently available pharmacotherapy of DM. 
Management of hyperglycemia with appropriate drugs can prevent both short 
term and long term complications of DM.1,6,7    
Drug utilization identifies the use of drugs in a society considering 
medical, social and economic consequences. Drug utilization study (DUS) can 
predict the rational use of drug in a population. Drug prescribed is considered 
rational if the patients receive medication appropriate to their clinical needs in 
doses that meet their own individual requirements for an adequate period of 
time and at the lowest cost to them and their community.8  
Adverse drug reaction (ADR) accounts for morbidity and repeated 
hospital admission. Identification of adverse drug reactions is lacking in 
studies conducted in India and ADR monitoring and reporting is in the stage of 
infancy in India. In a study done by Mandavi et al.9 it was pointed out that 3.4-
7% of hospitalization was due to ADR.            
      DM requires lifelong therapy and one of the important factor deciding 
compliance of patient is the cost of therapy. There is a wide variation in 
prescription of antidiabetic drugs with increasing concern about ADR and cost 
of therapy. Understanding the importance of DUS is rapidly growing 
worldwide. Hence rationality of antidiabetic therapy can be justified by treating 
the ailment with appropriate drug that can ensure immense therapeutic benefit 
in patients with least ADR and a minimum cost of therapy.9       
2 | P a g e  
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2. Justification: 
Response to antidiabetic agents varies in different population. 
Unawareness towards regional distribution of DM is a major drawback in 
India.10 Drug utilization research (DUR) establishes the current trend in the 
use of anti diabetic drugs and adverse drug reactions including the new drug 
and to identify irrational prescription. Irrational prescription can  affect  the  
adherence  to  drugs thereby  not reaching  therapeutic goal  ultimately  rising  
the economic burden.   
Till date no study on drug utilization pattern and ADR profile of 
antidiabetic drugs is conducted in this institution. Hence it has been proposed 
to conduct the study to evaluate the drug utilization pattern and ADR profile of 
antidiabetic drugs in the Medicine out-patient department (OPD) of this 
institution.      
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3. Aims and Objectives: 
To assess the following in the OPD of Medicine, Sree Mookambika 
Institute of Medical Sciences Kulasekharam (Kanyakumari district, Tamil 
Nadu): 
1. The pattern of antidiabetic drugs prescribed 
2. Rationality of using antidiabetic drugs as monotherapy and 
combination therapy 
3. Prescription writing pattern by brand name and generic name 
4. The pharmacoeconomics of antidiabetic drugs prescribed for one 
month  
5. To study adverse drug reaction profile of antidiabetic drugs prescribed  
4 | P a g e  
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4. Review of literature: 
4.1. Diabetes Mellitus: 
4.1.1. Introduction:  
DM is a chronic endocrine disorder characterized by high blood 
glucose concentration caused by insulin deficiency combined with insulin 
resistance.1 There is a growing prevalence of DM worldwide and a rise in the 
number of the affected people from 285 million to 438 million is expected by 
the year 2030 and may reach an epidemic proportion.10 Major proportion of 
increase is seen in developing country like India is facing a rapid rise in non 
communicable disease like DM along with communicable disease. The focus 
is still on infectious disease control and there is a gross negligence towards 
non-communicable disease.11       
This metabolic disorder predominantly affects the economically 
productive age group.12 If not managed rationally can lead to microvascular 
and macrovascular complication. Uncontrolled DM can result in a significant 
health burden on both family and the public.12  
4.1.2. History13,14 
 
Year Scientist Historical landmark 1910 Sir Edward Albert Sharpey-Schafer’s Insulin from latin word Insula - Island 1921 Frederick Banting and Charles best Extract insulin from dog pancreas 1923 Banting and Macleod  Nobel prize in  Physiology or Medicine     
Table No1: Historical landmark and the scientist contributed to DM  
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              GLP-1: Glucagon like peptide 1               DPP-4 inhibitors: Dipeptidyl peptidase 4 inhibitors                SGLT-2 inhibitors: Sodium glucose co-transport 2 inhibitors  
 
4.1.3. Definition:  
 “The term Diabetes mellitus describes a metabolic disorder of multiple 
aetiology characterized by chronic hyperglycemia with disturbances of 
Year Antidiabetic discovered 
1936 Protamine insulin 1955 Sulphonylurea 1990 Incretin hormone GLP-1 1995 Metformin 1996 Acarbose 1997 Thiazolidinediones 1998 Repaglinide 2005 Incretin mimetic - Exenatide 2005 Pramlintide 2006 DPP-4 inhibitors 2013 SGLT-2 inhibitors 
Table No 2: Discovery of antidiabetics 
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carbohydrate, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action or both.”15 
4.1.4. Epidemiology:10 
Indian population currently gaining the status of potential epidemic in 
India since individuals diagnosed with DM is more than 62 million. India 
topped the world with highest number of people (31.7 million) with DM in 
2000.1 Percentage of individuals in pre-diabetic state is 62.4 million. It is 
predicted that by 2030 patients in pre-diabetic state will be 101 million in 
India.16 Prevalence has been found to be equally affecting both the rural and 
urban population.5  
4.1.5. Classification of DM17,18 
DM is classified based on the pathological process that leads to 
hyperglycemia. The major common types of DM are : 
 
S. No Type Pathology Inducing hyperglycemia 
 
1. 
 
Type 1 DM 
 
 
β cell depletion:  
 Immune mediated or  
 Idiopathic 
      
2.  
 
Type 2 DM 
 
 
 Majority of cases due to insulin resistance 
 Insulin secretory defect predominates 
 Relative insulin deficiency 
3.  Gestational Pregnancy induced 
 
Table No 3: Major types of Diabetes mellitus 
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i. Genetic defects  Type of DM 
a. β cell function  
Hepatocyte nuclear transcription factor 4 α 
(HNF 4 α) 
Maturity Onset Diabetes of Young 1 
{MODY 1} 
Glucokinase MODY 2 
HNF 1 α MODY 3 
Insulin promoter factor-1 (IPF-1)  MODY 4 
HNF 1 β MODY 5 
Neuro DI 
 
MODY 6 
Mutation leading to β cell dysfunction Mitochondrial DNA 
Subunits of ATP sensitive potassium 
channel 
Proinsulin or Insulin  
b. Insulin action 
 
 Type A insulin resistance 
 Leprechaunism 
 Rabson-Mendenhall syndrome 
 Lipodystrophy syndromes 
ii. Others  
 
Wolfram’s syndrome 
Down’s syndrome   
Klinefelter’s syndrome  
Turner’s syndrome  
Friedreich’s ataxia  
Huntington’s chorea  
Laurence Moon-Biedl syndrome  
Myotonic dystrophy  
Porphyria  
Prader-Willi syndrome  
 
 
 
Table No 4: Genetic and immune mediated types of DM 
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Drug or chemical induced DM: 
Glucocorticoids, β adrenergic agonists, thiazides, hydantoins, α 
interferon, protease inhibitors, antipsychotics, nicotinic acid induces DM. 
Development of DM due to disease and infection of pancreas are: 
 
Defect Pathology 
i. Exocrine pancreas  Pancreatitis 
 Pancreatectomy 
 Neoplasia 
 Cystic fibrosis 
 Hemochromatosis 
 Fibrocalculous pancreatopathy 
 Mutations in carboxyl ester lipase 
ii. Endocrine disorder  Acromegaly 
 Cushing’s syndrome 
 Glucagonoma 
 Pheochromocytoma 
 Hyperthyroidism 
 Somatostatinoma 
 Aldosteronoma 
iii. Infection Congenital rubella, Cytomegalovirus, 
Coxsackievirus 
 
4.1.6. Factors contributing to the development of Diabetes mellitus:2,12 
Type 1 DM: 
Patients susceptible to autoimmune destruction of β cell is triggered by: 
Table No 5: Pancreatic disorders leading to development of DM 
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 Intra-uterine infection and low birth-weight 
 Viral infections like mumps, rubella, coxsackie B and cytomegalovirus 
 Chemical toxins  
 Dietary components 
 Environmental factors 
 Congenital rubella  
Type 2 DM: 
Factors pre-disposing to the development of type 2 DM can be either 
modifiable or non-modifiable.  
 
GLUT
K+
K+
ATP sensitive 
K+ channel
SUR1
G-6-P
Metabolism
Increase ATP
Decrease K+
Depolarization
Ca2+
Increase Ca2+
Stored insulin
Exocytosis
Pancreatic 
Beta cell
Increase 
plasma 
insulin
Glucose
 
Figure 1: Regulation of insulin secretion from pancreatic β cell 
Modified from Powers CA, D’Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In. Laurence LB, John SL, Keith LP editors. Goodman & Gilman’s Pharmacological Basis of Therapeutics 12thed. New Delhi. McGraw-Hill. 2011; p.1238-73.  10 | P a g e  
 
Review of Literature 
.i. Non-modifiable risk factors11 
 Age (more than 45 years) 
 Family history of diabetes 
 Diabetes during a previous pregnancy 
ii. Modifiable risk factors11 
 Physical inactivity  
 Diets rich in saturated fats and simple carbohydrates 
 Impaired glucose tolerance 
 Cigarette smoking 
 Increased consumption of alcohol  
 Obesity – risk in developing DM is 55% 
4.1.7. Pathogenesis:2,19,20 
Type 1 DM 
5 to 10% of type 1 DM develops due to autoimmune destruction of β 
cells of the pancreas. Manifestations of DM develop only after 70 to 80% of β 
cells are destroyed. Normal β cell mass is seen in individuals with genetic 
susceptibility at birth. Infection or environmental stimuli are the triggering 
factor for the autoimmune process. 
i. Genetic factors 
Major risk (40 to 50%) associated with DM is Human leukocyte antigen 
(HLA) locus on chromosome 6p21. It reflects the ability of specific HLA 
molecules to present self antigens. Non HLA genes also increase 
susceptibility to type 1 DM. Polymorphism of genes inhibiting T cell response 
can result in excessive T cell activation.       11 | P a g e  
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ii. Environmental factors 
Triggering factors involved in islet cell destruction are viral infection like 
mumps, rubella, coxsackie B and cytomegalovirus. Viral infections induce 
autoimmunity by: 
 Inducing islet injury and inflammation releasing sequestrated β cell 
antigens and activate auto reactive T cells 
 Producing proteins that mimic β cell antigens and immune response to 
the viral protein cross reacts with self tissue 
 Characteristic features of type 1 DM are:  
 Circulating insulin levels are low or very low 
 Patients are more prone to ketosis  
Type 2 DM: 
Lifetime risk of developing type 2 DM increases if both parents are 
affected. Variant of transcription factor 7 on chromosome 10q is associated 
with type 2 DM and impaired glucose tolerance. Genes involved in developing 
DM are not linked to immune regulation. 
Decreased response of peripheral tissue to insulin and β cell 
dysfunction is the metabolic defects that characterise this type of DM.    
Characteristic feature seen here are: 
 No loss or moderate reduction in β cell mass 
 Insulin in circulation is low 
 No anti β cell antibody is demonstrated 
 High degree of genetic predisposition 
12 | P a g e  
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 Late onset   
4.1.8 Mechanism of DM:2, 19 
Type 1 
In this type of disorder there is β cell destruction in pancreatic islets 
and autoimmune process starts years before the disease manifest. The major 
targets of immune attack includes insulin, β cell enzyme glutamic acid 
decarboxylase and islet cell autoantigen. In majority of cases there are 
autoimmune antibodies (Type 1A) that destroy β cells detectable in blood. 
Type 1 B is an idiopathic condition with no detectable β cell antibody. 
Type 2 
It is a multifactorial complex disease and majority (90%) of cases are 
due to type 2 DM. 
DM manifest due to abnormality in gluco-receptor of β cell so that they 
respond at higher glucose concentration. There may be reduced sensitivity of 
peripheral tissues to insulin, reduction in number of insulin receptors and 
down regulation of insulin receptors. Excess of hyperglycemic hormones or 
obesity can lead to relative insulin deficiency. 
4.1.9. Clinical features:2, 21 
 Polyuria: Increased urinary output  
 Polydypsia: Increased thirst 
 Polyphagia: Increase in appetite 
 Unexplained weight loss 
 Numbness in the feet, legs or hands 
 Healing of wound delayed 13 | P a g e  
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 Mood swings 
 Fatigue 
 Headache 
 Fainting 
4.1.10. Diagnosis:18 
 Glycosylated Haemoglobin [HbA1C] more than 6.5% 
 Fasting plasma glucose level > 126 mg/dl 
 Oral glucose tolerance test: Following a glucose load containing the 
equivalent of 75g anhydrous glucose dissolved in water and 2 hour 
plasma glucose shown above 200 mg/dl (or) 
 Presence of classical symptoms of hyperglycemia like polyuria, 
polydypsia, weight loss with polyphagia  and a random plasma glucose 
more than 200 mg/dl  
4.1.11. Pathological consequences:3,7,19,22,23 
DM can cause acute life threatening metabolic derangements like 
diabetic ketoacidosis and hyperglycemia hyperosmolar coma. Chronic 
complication can be:   
i. Macrovascular: Increase risk of myocardial infarction, stroke and lower 
extremity gangrene   
ii. Microvascular: Characteristic of DM patient includes retinopathy, 
nephropathy and neuropathy  
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4.1.12. Treatment:2 
Non-pharmacological: 
1) Balance diet rich in fibre and control of total calories and free 
carbohydrates intake 
2) Exercise 
3) Smoking cessation and reduction of alcohol intake 
Pharmacological:5 
1) Insulin 
2) Insulin secretagogue 
3) Glucagon-like Polypeptide-1 (GLP-1) Receptor Agonists 
4) DiPeptidyl Peptidase-4 (DPP-4) Inhibitors  
5) Insulin sensitizers 
6) α-Glucosidase Inhibitors  
Surgical:24 
Bariatric surgery involving resection of small intestine is indicated in 
type 2 DM with body mass index (BMI) more than 35 kg/m2.  Surgery can 
lead to normalization of glycemia in 40 to 95% of type 2 DM patients.  
4.2. Antidiabetic drugs:5,6,7,18,25-33 
Pharmacotherapy is mandatory to maintain an optimal glycemic control 
in the management of DM. DM can be treated either with oral hypoglycemic 
agents or parenteral insulin therapy. Different classes of antidiabetic drugs act 
at different parts of this glucose-insulin pathway which includes drugs that 
increase the amount of insulin secreted by the pancreas, increase the 
sensitivity of target organs to insulin and decrease the rate at which glucose is 15 | P a g e  
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absorbed by the gastrointestinal tract. The number of available oral 
hypoglycemic agents shows a transient rise in the last decade. Decision 
making by physicians has become complex with more therapeutic options. 
Treatment of diabetes requires a progressive pharmacological approach.  
Irrational management of DM and its adverse effect can have a major public 
health impact.3     
4.2.1. Classification 
 
 
Sl. No Class Drugs 
1. Insulin Rapid-acting: Lispro, Aspart, 
Glulisine  
Short acting: Regular 
Intermediate acting: NPH  
( Neutral Protamine Hagedorn 
or Isophane ) 
Long acting: Detemir, Glargine 
2, Sulphonylurea First generation: 
Chlorpropamide 
Tolbutamide 
Second generation:  
Glibenclamide (Glyburide) 
Glimepiride 
Glipizide 
Gliquidone 
Gliclazide 
3. Meglitinides Repaglinide 
Nateglinide 
4. Glucagon like peptide 1 agonist Exenatide 
Table No 6: Classification of antidiabetic drugs 
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Liraglutide 
5. Dipeptidyl peptidase-4 inhibitor  Sitagliptin 
Vildagliptin  
Saxagliptin 
Alogliptin 
Linagliptin 
6. Biguanides Metformin 
Phenformin 
Buformin 
7. Thiazolidinediones Pioglitazone 
 8. α- glucosidase inhibitor Acarbose 
Miglitol 
Voglibose 
 9.  Amylin agonist Pramlintide 
10. Sodium-glucose co-transport-2 
(SGLT-2) inhibitor 
Dapagliflozin 
 
4.2.2. Individual classes of Drugs: 
4.2.2.1. Insulin:  
Insulin is the choice of drug for all forms of DM and bioavailable only 
when administered parenterally. Clinically used insulin is expressed in 
international units. One unit of insulin reduce blood glucose concentration in 
fasting rabbit to 45 mg/dl. Insulin absorption and pharmacokinetics are 
modified by two approaches: 
 Formulation slowing absorption following subcutaneous injection 
 Human insulin protein structure and aminoacid sequence alteration  
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1. Rapid-acting: 
Very fast onset and duration of action is short (4 to 5 hours). It has 
comparatively a lowest variability of absorption (5%). 
i. Insulin Lispro: First monomeric insulin analog produced by 
Recombinant technology. Structure of insulin altered by reversal of 
amino acid in the carboxy terminal of B-chain (B28: Proline, B29: 
Lysine). Onset of action seen in 5 to 15 min and peak activity at 1 hr.     
ii. Insulin Aspart: Modification of Insulin by substitution with aspartic acid 
at B28 (proline) there by inhibiting Insulin aggregation.  
iii. Insulin Glulisine: Lysine substituted at B3 and glutamic acid at B29. 
These modifications alter the downstream of events in insulin receptor 
substrate 2 (IRS-2) pathway. 
2. Short-acting: 
Soluble crystalline zinc Insulin: 
Effect of insulin appears within 30 minutes and peak effect occurs 
within 2 to 3 hour. Regular insulin molecules aggregate to form dimers which 
stabilize around zinc ions to form hexamers. Action is based on hexameric 
nature of regular Insulin. Disadvantage of using regular insulin are delayed 
absorption, dose dependent duration of action of insulin and variability of 
absorption (25%). It is the only insulin that can be administered intravenously 
because on dilution hexamers immediately dissociate into monomers.  
3. Intermediate-acting: 
Absorption of NPH is delayed by combining appropriate amount of 
insulin and protamine so that it is in a complex state. After subcutaneous 18 | P a g e  
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injection proteolytic tissue enzymes degrade protamine to permit absorption of 
insulin. Onset of action in 2 to 5 hrs and duration of action is 4 to 12 hrs. 
4. Long-acting:  
Insulin Glargine: 
This is the soluble long acting preparation and has a slow onset of 
action (1 to 1.5 hrs) and maximum effect seen after 4 to 6 hrs. Two arginine 
molecules attached to B–chain carboxyl terminal and glycine at A21 position. 
This altered analog is soluble in acidic solution but precipitates at body neutral 
pH. Insulin from crystalline depot slowly dissociates to maintain a low 
continuous level of circulating insulin. It should not be mixed with other insulin 
(to maintain solubility, the formulation is maintained at acidic pH). 
Insulin Detemir: 
This is recently developed long acting insulin. Onset of action is 
between 1 to 2 hrs which is dose dependent with duration of action for more 
than 12 hrs. Terminal threonine is dropped from B30 and myristic acid is 
attached to terminal B29. This modification increase both self aggregation and 
reversible albumin binding thereby prolonging the availability of injected 
insulin. Development of hypoglycaemia is minimal compared to NPH. 
Mechanism of action: 
Insulin receptor is a heterotetrameric glycoprotein consisting of 2 
extracellular α and 2 transmembrane β subunit linked by disulfide bonds. 
Insulin binding site is present in α subunit while tyrosine protein kinase activity 
is in β subunit. Binding of insulin to α subunit, internalise the receptor and 
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β subunit increase the tyrosine phosphorylation of Insulin receptor substrate 
proteins. Activation of phospholipase C generates certain second messengers 
like phosphotidyl inositol glycan and diacylglycerol.  
 Both phosphorylation and second messengers are involved in the rapid 
metabolic action of Insulin. 
 Stimulates transport of glucose across cell membrane by ATP 
dependent translocation of glucose transporter 4 (GLUT4) and GLUT1 
to plasma membrane.    
 Promote expression of genes directing synthesis of GLUT. 
Fate of internalized receptor-insulin complex: 
 Degraded intracellularly 
 Return back to surface  
Indication: 
1. Type 1 and 2 DM  
2. Diabetic ketoacidosis: Life threatening medical emergency caused by 
inadequate insulin replacement. Commonly seen in- 
 Type 1 DM – Newly diagnosed or interrupted insulin 
replacement 
 Type 2 DM – Concurrent stressful condition (sepsis, 
pancreatitis, high dose steroid therapy) 
Clinical presentation: 
Nausea, vomiting, abdominal pain, deep slow breathing (Kussmaul), 
changes in mental status, elevated blood and urinary ketones and 
glucose, low arterial pH and bicarbonate. 
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3. Hyperosmolar hyperglycemic syndrome: Type 2 DM patient with 
hyperglycemia and dehydration.  
Predisposing factor: 
 Inadequate oral hydration 
 Elderly 
 Drugs – Phenytoin, steroids, diuretics, β blockers 
 Peritonealdialysis and haemodialysis 
Clinical presentation: 
Declining mental status, seizure, plasma glucose > 600mg/dl 
Adverse drug reaction: 
1. Hypoglycemia: Most common complication due to- 
 Inadequate carbohydrate consumption 
 Unusual physical exertion 
 Too large dose of insulin 
Clinical presentation: 
 Intact hypoglycemic awareness 
Sympathetic (tachycardia, palpitation, sweating)  
Parasympathetic (nausea, hunger) 
 Hypoglycemic unawareness 
Important feature found in patients exposed to frequent 
episodes of hypoglycemia. These patients lack early warning 
sign of reduced plasma glucose concentration. By preventing 
repeated exposure to hypoglycemia, awareness can be 
restored.  
 21 | P a g e  
 
Review of Literature 
2. Insulin allergy: 
Local or systemic urticaria due to histamine release from tissue mast 
cell sensitised by antiinsulin immunoglobulin E (IgE) antibodies. 
3. Immune insulin resistance: 
Patients on insulin always have a circulating immunoglobulin G (IgG) 
antiinsulin antibody at a low concentration which will neutralize the 
action of insulin to a negligible extent. Sometimes insulin resistance 
may develop due to the auto antibodies. 
4. Lipodystrophy:  
Animal insulin preparation may produce atrophy of subcutaneous fatty 
tissue at the site of injection 
5. Increased cancer risk: 
Due to insulin resistance and hyperinsulinemia 
Contraindications: 
 During episodes of hypoglycemia 
 Hypersensitive to insulin 
4.2.2.2. Sulphonylurea: 
Sulphonylurea were the first widely used oral antidiabetic treatment. 
Sulphonylurea are approved for use as monotherapy and in combination with 
insulin and other oral hypoglycemic agents (OHA) except with rapidly acting 
secretagogues.         
Route of administration: Oral and advice to take immediately before meals. 
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Mechanism of action: 
Sulphonylurea binds to β cell sulphonylurea receptor 1 (SUR-1) [Part of 
transmembrane complex with adenosine 5’-triphosphate sensitive potassium 
adenosine triphosphate channel (K ATP channel)]. Binding of sulphonylurea to 
the SUR-1 receptor closes the KATP channel. Depolarisation open voltage 
dependent calcium channel and activation of calcium-dependent protein 
release insulin granules by exocytosis. Later insulin action declines but there 
are sensitization of the target tissue to the action of insulin. This is due to 
increase in the number of insulin receptor and there is reduction in HbA1C 
level by 1 to 2%.20 
Adverse drug reaction: 
i. Hypoglycemia  
20% report one episode annually. Insulin release is initiated when 
glucose concentration are below the normal threshold for glucose-
stimulated insulin release. Elderly diabetic patients who were treated 
with sulphonylurea have a 36% increased risk of hypoglycemia 
compared to younger patients.  
ii. Transient cutaneous reaction 
iii. Fever, jaundice, blood dyscrasia  
iv. Chlorpropamide with alcohol cause facial flushing 
v. Chlorpropamide increase renal sensitivity to anti diuretic hormone 
causing water retention with hyponatremia 
vi. Weight gain of 1 to 4 kg and stabilize after 6 months. It is due to 
anabolic effect of increased plasma insulin concentration. 
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Drug Interactions 
Drugs increasing sulphonylurea action are phenylbutazone, salicylates, 
sulphonamides, sulfinpyrazone which displace sulphonylurea from the protein 
binding sites. Cimetidine, ketoconazole, sulphonamides, warfarin, 
chloramphenicol and acute alcohol intake can Inhibit the metabolism of 
sulphonylureas. Salicylates, propranolol, sympatholytic antihypertensive, 
lithium, theophylline and alcohol can prolong the pharmacodynamic action of 
sulphonylureas. 
Figure 2: Mechanism of action of Sulphonylurea and Meglitinide 
Modified from Powers CA, D’Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In. Laurence LB, John SL, Keith LP editors. Goodman & Gilman’s Pharmacological Basis of Therapeutics 12thed. New Delhi. McGraw-Hill. 2011; p.1238-73.  
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Drugs decreasing sulphonylurea action are phenobarbitone, phenytoin, 
rifampicin, chronic alcoholism which may induce the metabolism of 
sulphonylurea. Corticosteoids, thiazide, furosemide and oral contraceptives 
will suppress the insulin release due to sulphonylurea. 
Contraindication: 
i. History of hypersensitivity 
ii. Diabetic ketoacidosis 
iii. Hepatic disease 
iv. Renal disease    
v. Pregnant and lactating ladies 
4.2.2.3. Meglitinide / D-phenylalanine analogues:  
Meglitinides are novel antidiabetic medicine and can be given in 
combination with other antidiabetic drugs when hyperglycemia is not 
controlled.   
Route of Administration: Oral, half an hour before each meal 
Mechanism of action: 
Meglitinides are highly tissue selective and have a low affinity for heart 
and skeletal muscle. It binds with the ATP dependent potassium channel in 
the β cell of pancreas but the site is distinct from that involved in 
sulphonylurea binding. Binding of meglitinide to the potassium channel will 
block the potassium channel and increases the calcium influx and induces 
insulin secretion. They are effective in lowering glycated haemoglobin level by 
0.6 to 1%.  
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Adverse drug reaction: 
i. Hypoglycemia: 16% of patients (Because of short lasting action, risk of 
hypoglycemia is less) 
ii. Headache, dyspepsia, arthralgia, weight gain 
iii. Dizziness, nausea, flu like symptoms, joint pain 
Contraindication: 
i. Hepatic dysfunction 
ii. Diabetic ketoacidosis 
iii. Type 1 DM 
iv. Known hypersensitivity reaction 
4.2.2.4. Incretin based therapy:  
            Insulin and glucagon levels are influenced by incretin hormones called 
 GLP-1 secreted by the intestinal glucose responsive neuroendocrine 
(L) cells of the intestinal mucosa after a meal 
 Glucose dependent insulinotropic polypeptide (GIP) secreted by 
intestinal K cells located in the jejunum and throughout the gut 
      Both exert an insulinotropic effect (glucose dependent secretion of 
insulin).  GLP-1:  
 Stimulates insulin secretion and inhibits glucagon secretion under 
hyperglycemic condition 
 Slows gastric emptying and acts as a mediator of satiety in the central 
nervous system 
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Incretin effect is the phenomenon by which greater insulin secretion 
occurs after oral glucose intake than after the infusion of comparable amounts 
of intravenous glucose. 
Patients with type 2 diabetes lack the insulinotropic response to GIP. 
GLP-1 levels may be reduced in this patient population resulting in a much 
more physiological regulation of α and β cell function and minimize the risk for 
hypoglycemia.    
GLP-1 and GIP are rapidly degraded by the proteolytic enzyme DPP-4 
and thus are available only for a very short time.     
4.2.2.4.A. Incretin mimetic: Exenatide, Liraglutide    
Route of administration: Subcutaneous injection, administered in the 
abdomen, thigh or upper arm 
Mechanism of action 
Incretin mimetics are synthetic peptide. It is DPP-4 resistant analogue 
which exhibits same biological effect as GLP-1. It has a longer half life. 
Results in a significant reduction in glycosylated haemoglobin level and 
reduce body weight. 
Adverse drug reaction 
i. Nausea, vomiting in 50% recipients 
ii. Diarrhea 
iii. Acute pancreatitis 
iv. Hemorrhagic or necrotizing pancreatitis 
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Contraindication: 
Renal impairement 
4.2.2.4.B. Dipeptidyl peptidase-4 inhibitors:  
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Figure 3: Mechanism of action of DPP-4 inhibitors 
Modified from Tripathi KD. Essentials of medical pharmacology. 7th ed. New Delhi: Jaypee brothers medical publishers; 2013. p.512-38.   
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Route of administration: Oral 
Mechanism of action: 
DPP-4 inhibitors prevent the degradation of GLP-1 and GIP thus 
increasing endogenous incretin level 
Adverse drug reaction: 
 Nausea 
 Loose stools 
 Rashes 
 Allergic reaction 
 Upper Respiratory tract infections 
 Dizziness 
 Influenza 
 Headache 
 Hepatotoxicity reported with vildagliptin 
 Nasopharyngitis and cough due to prevention of substance P 
degradation 
Contraindication: 
History of hypersensitivity reaction 
4.2.2.5. Biguanides: 
Biguanides are insulin sensitizers which reduce hepatic glucose output 
and increase in utilization of glucose by the peripheral tissues. A very salient 
feature of this class of drug is associated with weight loss and lower incidence 
of hypoglycaemia as monotherapy. 
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Route of Administration: Oral 
Mechanism of action: 
Presence of insulin is essential for their action. Mechanism by which 
metformin exerts its antihyperglycemic effect are not entirely clear. Adenosine 
5’ monophosphate activated protein kinase (AMPK) is a intracellular target of 
metformin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Effect of Metformin 
Intestine: Increase anaerobic glucose metabolism 
Liver: Decrease glyconeogenesis              Decrease glycogenesis              Decrease oxidation of fatty acid 
Fat: Increase glucose uptake and oxidation 
Muscle: Increase glucose uptake and oxidation                  Increase glycogenesis                  Decrease oxidation of fatty acid  
Decrease blood glucose concentration 
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They reduce the HbA1C by 1 to 2%. 
Non Diabetic Indication: 
Anovulatory polycystic ovary syndrome (PCOS) – improvement of 
insulin sensitivity cause ovulation to resume  
Adverse drug reaction: 
i. Abdominal discomfort and diarrhea 
ii. Nausea, metallic taste, tiredness  
Lactic acidosis – Increase in blood lactate because it is poorly 
concentrated in hepatic cells. Precipitated by alcohol ingestion. 0.03 
cases per 1000 patient-years or 1 case per 33,000 patient-years. 
Phenformin and buformin were withdrawn in 1980s due to lactic 
acidosis which can be fatal 
iii. Vitamin B12 deficiency due to interference with its absorption 
Drug interaction: 
Cimetidine and furosemide compete with metformin excretion and 
enhance its toxicity 
Contraindication: 
 Impaired renal function 
 Conditions predisposing to hypoxia or reduced perfusion 
 Liver disease 
 Alcohol abuse 
 History of metabolic acidosis  
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4.2.2.6. Thiazolidinediones: 
Glitazones were introduced in the year 1997. The most prominent 
effect of thiazolidinediones is to increase insulin stimulated glucose uptake by 
skeletal muscle cells.  
Route of Administration: Oral  
Mechanism of action: 
Peroxisome prolferator activated receptors (PPARs) are transducer 
proteins belonging to nuclear receptor super family. PPAR gamma is a 
transcription factor activated by thiazolidinediones. On transactivation, which 
is DNA dependent, PPAR gamma forms a heterodimer with the Retinoid X 
receptor (RXR). Specific DNA response elements called PPAR Response 
Elements (PPRE) are recognized in the promoter region of the target genes.  
Peroxisome proliferator activated receptor gamma (PPAR gamma) is 
expressed at highest level in adipose tissue and less in muscle and liver. 
They promote differentiation of pre-adipocytes with lipogenesis that enhance 
the local effect of insulin occurs. Increased glucose uptake via GLUT-4 in 
skeletal muscle and reduce the production and activity of adipocyte derived 
cytokine tumour necrosis factor α (TNF α) implicated in the development of 
impaired insulin action in the muscle. 
Adverse drug reactions: 
 Fluid retention 
 Weight gain 
 Myalgia 
 Mild anemia 
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 Increased risk of heart failure 
 Hepatitis and liver damage 
 Troglitazone were withdrawn in 2000 due to risk of hepatitis and liver 
damage 
 Rosiglitazone use for 12 months is associated with a significantly 
increased risk for myocardial infarction and heart failure 
Drug Interaction: 
 Failure of oral contraception 
 Ketoconazole inhibits metabolism – Increase the concentration of 
pioglitazone 
 Rifampicin induces metabolism – Decrease the concentration of 
pioglitazone 
This is because pioglitazone is metabolised by both CYP2C8 and CYP3A4 
Contraindication: 
 Diabetic ketoacidosis 
 Active liver disease 
 Heart failure 
 Insulin treatment: Greater fluid retention, weight gain and precipitation 
of congestive heart failure 
 Pregnancy and breast feeding 
4.2.2.7. α - Glucosidase inhibitors:  
 
α - glucosidase inhibitor competitively inhibits enzymes in the small 
intestine that are responsible for breakdown of oligosaccharide and 
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specific pathophysiologic aspects of diabetes. There is a surprising 
improvement in the post prandial plasma glucose level. They are most useful 
in combination with other oral hypoglycemic agents. 
Route of administration: Oral and taken with meals 
Mechanism of action: 
α glucosidase enzyme is present in the brush border of enterocytes 
lining the intestinal villi completing the carbohydrate digestion. Α glucosidase 
inhibitors competitively inhibit the activity of this enzyme preventing the 
cleaving of normal disaccharide into monosaccharide prior to absorption. The 
average HbA1C lowering effect is about 0.5 to 1% which is comparatively 
lesser than other class of OHA. They alter the release of intestinal hormone 
that enhances nutrient induced insulin secretion.  
They retard glucose entry into systemic circulation and lower post prandial 
glucose level. 
Adverse drug reaction: 
 Flatulence  
 Abdominal discomfort  
 Diarrhea occur in about 20% of patients. It is due to carbohydrates 
fermented by the flora of the large bowel.  
Gastrointestinal side effect can be minimized by initiating therapy at a 
low dose with slow titration upward and symptoms diminish with continued 
use.  
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Drug Interaction: 
 Gastrointestinal effect of acarbose is influenced by the drugs affecting 
gut motility. 
 Cholestyramine increases the glucose lowering effect of acarbose. 
Contraindication: 
 Irritable bowel syndrome 
 Severe kidney or liver dysfunction 
 Inflammatory bowel disease 
 Colon ulcer 
 Partial intestinal obstruction 
 Chronic intestinal disease 
4.2.2.8. Amylin agonist: 
      Islet amyloid peptide (IAP) is a hormone secreted along with insulin by 
the β cell of pancreas in response to insulin secretagogues. It is found to be 
deficient in diabetics. IAP acts in the brain to:  
 Reduce glucagon secretion from α cells 
 Delay gastric emptying 
 Retard glucose absorption 
 Promote satiety 
Pramlintide (Triptro-amylin) is an amylin analog and found to control 
blood sugar level. Studies have shown reduction in fructosamine which is a 
surrogate marker of hyperglycemia.  Glycated haemoglobin reduction is 
around 0.5 to 1%.. It is found to produce significant weight loss.  
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Route of administration: Subcutaneous Injection 
Adverse drug reaction: Nausea, vomiting 
4.2.2.9. Sodium-glucose co-transport-2 inhibitor: 
Glucose filtered at glomerulus is reabsorbed in proximal tubules by a 
major transporter SGLT-2 which induces glucosuria and lower blood glucose. 
Dapagliflozin is SGLT-2 inhibitors and the adverse effects expected 
due to glycosuria are urinary and genital infections, electrolyte imbalance and 
increased urinary frequency. 
4.2.3. Guidelines for management of DM:18,34 
4.2.3.1. Canadian Diabetes Association (CDA) Practice Guidelines Expert 
Committee: 
Type 1 DM 
Initiated on Insulin immediately at diagnosis. In Intensive diabetes 
management the glycemic targets are achieved by administering basal bolus 
insulin regimens or Continuous Subcutaneous Insulin Infusion (CSII)   
Hypoglycemia has to be minimized, glycated haemoglobin has to be 
Improve and post prandial glucose targets have to be achieved. Rapid acting 
bolus insulin analogues in combination with adequate basal insulin has to be 
used instead of regular insulin in these cases. 
Type 2 DM 
Initiation of anti hyperglycemic medication is required if glycemic 
targets are not achieved within 2 to 3 months of lifestyle management. 
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Antihyperglycemic must be added to attain targeted HbA1C within 3 to 6 
months. 
Patients with marked hyperglycemia (HbA1C > 8.5%) should be 
initiated preferably combination therapy one of which may be insulin. Therapy 
started concomitantly with life style management.  
Metformin should be the initial drug of choice unless contraindicated. 
Additional antihyperglycemic agents are selected on the basis of: 
1. Patient characteristics: 
 Degree of hyperglycemia 
 Presence of comorbidities 
 Patient preference and ability to access treatment 
2. Properties of the treatment: 
 Contraindications to drug 
 Glucose lowering effectiveness 
 Risk of hypoglycemia 
 Effectiveness in reducing diabetes complication 
 Effect on body weight 
 Side effects 
Patients initiated with insulin or insulin secretagogues must be 
counselled about the prevention, recognition and treatment of drug-induced 
hypoglycemia   
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4.2.3.2. American Diabetes Association (ADA) Guidelines: 
Type 1 DM 
Most people with type 1 DM must be treated with multiple dose insulin 
(MDI) injection (3 to 4 injections per day of basal and prandial insulin) or CSII 
must be educated in how to match prandial insulin dose to carbohydrate 
intake, premeal blood glucose and anticipated activity 
Type 2 DM 
Preferred initial pharmacological agent for type 2 DM is metformin if not 
contraindicated and if tolerated. Newly diagnosed type 2 DM patients with 
elevated blood glucose levels or HbA1C consider insulin therapy with or 
without additional agents. If noninsulin monotherapy at maximum tolerated 
dose does not or achieve or maintain the HbA1C target over 3 months, add a 
second oral agent, a GLP-1 receptor agonist or insulin. Patient-centred 
approach should be used to guide choice of pharmacological agents. Due to 
the progressive nature of type 2 DM, insulin therapy is eventually indicated for 
many patients with type 2 DM  
4.2.4. Therapeutic uses: 
 Type 1 Diabetes mellitus 
 Type 2 Diabetes mellitus 
 Polycystic ovarian syndrome 
 Diabetic ketoacidosis 
 Hyperosmolar coma 
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4.2.5. Recent advances:35 
Currently available drugs for the treatment of DM do no cure this 
disorder. Symptoms return once the treatment is terminated. Development of 
novel drugs may bring about a change in the treatment modality.  
i. D2 Dopamine agonist: 
Bromocriptine activate the D2 dopaminergic receptors and alters 
hypothalamic control of insulin sensitivity in peripheral tissue. Taken early in 
the morning thought to act on hypothalamic dopaminergic control of circadian 
rhythm of hormone release and reset it to reduce insulin resistance. 
Reduction in glycated haemoglobin is around 0.5%.  
Adverse drug reaction: Constipation, dyspepsia, abdominal pain, nausea,  
intestinal obstruction. 
ii. β 3 adrenoreceptor agonist: 
 
β 3 adrenoreceptor agonist showed marked selectivity for stimulation of 
lipolysis and hence for oxygen and energy consumption in skeletal muscle 
and adipose tissue. In certain type of fat cells, β cell activation induces the 
expenditure of metabolic calories as heat. 
iii. Liver selective glucocorticoid antagonist 
Glucocorticoids increase blood glucose level by antagonising the action 
of insulin. Glucocorticoid antagonist increase glucose disposal and inhibit 
hepatic glucose production by enhancing the action of insulin.  Mifepristone is 
found to exhibit glucocorticoid antagonism.   
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iv. Glycogen synthase kinase 3 (GSK-3) 
GSK-3 is a key enzyme involved in glycogen metabolism. It has been 
found to phosphorylate insulin receptor substrate. Lithium found to have 
insulin like effect by inhibiting GSK-3. 
v. Selective inhibitors of Fructose 1, 6 bisphosphatase (FBPase) 
Gluconeogenesis increases the endogenous glucose production. 
FBPase inhibitors may originate as a new class of antidiabetic drug by 
reducing gluconeogenesis.  
vi. Anakinra 
Interleukin 1 production is blocked by recombinant human interleukin-
1receptor antagonist anakinra. Interleukin 1 β is released due to high glucose 
level which can reduce the function of β cell.  
vii. Stem cell therapy 
Effective in type 1 DM. Stem cells from cord blood found to restart the 
function of pancreas by reducing the need for insulin.  
4.3. Drug utilization study:36-44  
Drugs prescribed in clinical practice are mainly based on the evidence 
provided by the pre marketing and post marketing period. Data created from 
the post marketing period are needed to provide an adequate basis for 
improving drug therapy. Studies on drug utilization are a potential tool used to 
evaluate health systems. Tremendous improvement in the marketing of new 
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drugs, variation in the pattern of drug prescribed, delayed adverse effects and 
cost of drug as increased the importance of DUS.  
The principal focus of DUS is to imply prescription of drug in an optimal 
dose on the right indication with the correct information and at an affordable 
price thereby facilitating rational use of drugs in a population. DUS contribute 
to rational drug use by increasing our understanding of how drugs are used, 
generate early signals of irrational use of drugs and enable us to intervene to 
improve drug therapy.  
4.3.1. Definition: 
“Drug utilization is defined as the marketing, distribution, prescription 
and use of drugs in a society with special emphasis on the resulting medical, 
social and economic consequences.” 
4.3.2. Types of Drug use information: 
1. Drug based information 
2. Problem or Encounter-based information 
3. Patient information 
4. Prescriber information   
4.3.3. Sources of drug utilization data: 
      Data’s on drug utilization can be from: 
 Medical practices  
 Health facility 
 Local manufacturer 
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 Whole sale dealers 
 Drug importers  
Drug utilization data can be obtained from quantitative and qualitative 
studies. 
Quantitative studies describe the present state and trends in drug 
prescribing and drug use at various level of health care system. It is obtained 
from: 
 Collected Data 
 Surveys  
Qualitative study assess appropriateness of drug utilization and link 
prescribing data to indications for prescribing. Quality indicators of drug use 
are: 
 Average number of drugs per prescription 
 Percentage of drugs prescribed by generic name 
 Percentage of drugs prescribed from essential drug list 
 Average cost of drugs per prescription    
Data from medical practices can be used to generate indicators that 
provide information on prescribing habits. These indicators determine whether 
drug use problem exist. This can motivate health care providers to follow 
established health care standards 
      Databases currently available for purpose of DUS classified as: 
 Non-diagnosis linked describe drug consumption in a population 
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 Diagnosis linked consider drug utilization linked to its indication 
and outcome 
4.3.4. Instruments for data collection: 
i. Patient files  
ii. Computer registries   
iii. Home inventories  
iv. Questionnaires  
v. Self reported data (subject to recall inaccuracy) 
4.3.5. Objectives: 
1. Ensuring that drug therapy meets current standards of care   
2. Evaluating the effectiveness of drug therapy     
3. Preventing medication related problems     
4. Controlling cost of drug    
5. Identification of areas of practice that require further education of 
practitioners 
6. Identify problems and define areas for further investigation on the 
absolute and relative efficacy and safety of drug therapy 
7. Suggest overuse, under-use or misuse of single drug compound or 
therapeutic classes of drugs 
8. Aid in the determination of benefit risk and cost-effectiveness 
9. Facilitate rational use of drug 
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4.3.6. Clinical importance:  
Application of the theory of the evidence-based medicine into the 
everyday practice means critically appraising the evidence for validity and 
clinical usefulness. Data regarding drug use pattern can validate evidence-
based practice and form the basis of decision making processes. There is a 
growing evidence that suboptimal use of drug including preventable drug 
related morbidity (PDRM) and mortality, is at least as costly as the 
prescription drug themselves.  Drug utilisation study holds the promise that if 
implemented effectively it could partially address the problem by enhancing 
the appropriate use of drugs. Improved safe and effective drug use may 
restrain rising drug expenditure and by reducing PDRM, reduce hospital 
admission and other avoidable health care cost. Databases created as a 
result of DUR efforts have been used in new and innovative ways to 
incorporate health outcomes data and disease management interventions. 
Additional outcomes data, combined with quality assurance efforts, should 
increase the utility of DUR/disease management efforts in evaluating health 
systems while improving the effectiveness and efficiency of health care 
interventions. 
4.3.7. Factors influencing drug utilization: 
1. Population related factor: change in total population, change in 
population demographic, change in health status of a population 
2. System related factor: change and transition associated with health 
system reform and restructuring changes in policies and programs 
3. Research and technology related: new treatment approach   
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4. Pharmaceutical industry: development of new drug product, promotion 
of drugs to physician, drug sampling, direct to consumer advertising 
5. Practice and people related: change in prescribing and dispensing 
practice  
4.3.8. Uses of DUS:  
i. Facilitate rational use of drug 
ii. Increase our understanding of how drugs are being used 
iii. Generate hypothesis that set the agenda for further investigation and 
thus avoid prolonged irrational use of drugs 
iv. Assess whether interventions intended to improve drug use have had 
the desired impact 
v. By comparing data from different localities may identify  and promotion 
of best practice  
4.4. Pharmacovigilance45-50               
Pharmacovigilance is an important post-marketing tool in ensuring the 
safety of pharmaceutical product. It involves evaluating information gathered 
from the health care providers, pharmaceutical company and patients in order 
to understand the risks and benefits of a particular drug. These activities: 
 Identify new information about adverse effects of the drug 
 Prevent harm to the patient 
Major role of pharmacovigilance is to identify and evaluate safety 
signals. Safety signal refers to concern about an excess of adverse events 
compared to that would be expected with a product use.     
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4.4.1. Terminology: 
Pharmacovigilance:47 
 “Pharmacovigilance is the pharmacological science relating to the 
detection, assessment, understanding and prevention of adverse effects 
particularly long term and short term side effects of medicines.”  
Adverse event or adverse experience:47 
An adverse event is an unfavourable and unintended sign, symptom or 
disease temporarily associated with the use of a medicinal product whether or 
not related to the medicinal product. 
Adverse drug reaction:47 
An ADR is a response to a drug which is noxious and unintended and 
which occurs at a dose normally used by man for prophylaxis, diagnosis or 
therapy of disease or for modification of physiological function. 
Serious adverse event or serious adverse drug reaction: 
A serious adverse event or reaction is any untoward medical occurrence 
that at any dose results in death or is life threatening. Life threatening refers to 
an event in which patient was at risk of death at the onset of event like: 
 Inpatient hospitalization or prolongation of existing hospitalization 
 Persistent or significant disability 
 Congenital anomaly or birth defect 
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4.4.2. History: 
 1986 Pharmacovigilance in India.  
 1997 India joined WHO adverse drug reaction monitoring programme 
based in Uppsala, Sweden. 
 2005 WHO sponsored and World bank funded National 
Pharmacovigilance programme in India. 
4.4.3. Objectives:48-50 
i. To monitor ADRs in Indian population 
ii. To create awareness amongst health care professionals about the 
importance of  ADR reporting in India  
iii. To monitor benefit-risk profile of medicines 
iv. Generate independent, evidence based recommendations on the 
safety of medicines 
v. Support the centre for drug standard control organization (CDSCO) for 
formulating safety related regulatory decisions for medicines  
vi. Communicate findings with all key stakeholders 
vii. Create a national centre of excellence at par with global drug safety 
monitoring standards  
viii. To keep in track the long term drastic effects of drug 
ix. Contribute to the rational use of drug 
4.4.4. Clinical importance:50 
New drug released into market lack long term safety data. Prescribed 
drugs response varies due to interactions with drug and food.  Awareness 
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about pharmacovigilance and practice according to it has a large impact on 
health care quality. Information on clinical, pathological and epidemiological 
information related to adverse reaction help us to fully understand adverse 
effects of drugs and for identifying patients at risk. ADR have the potential to 
provide insight into structure-activity relationship, pharmacokinetic, 
pharmacodynamic and genetic factors affecting the action of drugs. This may 
provide lead for other novel indications of the drug. Knowledge acquired 
following stringent monitoring on adverse effect of drug can prevent 
unnecessary suffering by patients and decrease financial loss of the patient 
due to inappropriate use of drug.     
4.4.5. Current status in India:48 
India is the fourth largest producer of pharmaceuticals in the World. 
Clinical trials involve lesser number and only a selected group of patients. 
Hence when  drug enters the market less common adverse effects are not 
known. Benefit-risk ratio of pharmaceutical product is a dynamic variable and 
must be continuously monitored. Pharmacovigilance is in the stage of infancy 
in India.8                 
Most of the drug launched till date were already approved and 
marketed in other countries. Assessment of benefit-risk and appropriate 
changes were made from the experience gained from these markets. Hence 
pharmacovigilance was considered to be non-vital. Implementation of internal 
pharmacovigilance standards to detect adverse drug events cannot be 
ignored since the Indian drug companies started bringing their own research 
molecules.  
48 | P a g e  
 
Review of Literature 
Pharmacovigilance Programme of India (PvPI) was initiated by 
Government of India on 14th July 2010 with the All India Institute of Medical 
Sciences (AIIMS), New Delhi as the National coordination centre for 
monitoring ADRs in the country for safe-guarding public health. 22 ADR 
monitoring centre was set up under this programme in the year 2010. On 15th 
April 2011 the National coordinating centre was shifted to the Indian 
Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh. 
4.5. Studies related to drug utilization of antidiabetic drugs: 
Prescription pattern analyzed and the results published by Olurishe et 
al.4 showed that number of drugs per prescription was 5.29.  Large number of 
patients treated with combination of metformin and glibenclamide. 
Hypertension was found to be the commonest co-morbid disease.     
 In a retrospective study on adherence to OHA therapy was conducted 
by Stephen et al.51 showed distribution of antidiabetic drugs were as 
sulphonylurea-66.4%, metformin-24.3%, troglitazone-6.6%, repaglinide-1.5% 
and α glucosidase inhibitor-1.1%. 
 Johnson et al.52 studied utilization of diabetic medication for type 2 DM. 
Percentage of patients receiving antidiabetic therapy as monotherapy was 
54.6%, oral combination therapy in 31.9% and oral with insulin combination 
therapy in 9.2% and remaining  were on other antidiabetic drugs.  Among 
monotherapy metformin in 24.6% was the most common and 
thiazolidinediones in 0.1% was the least prescribed drug for management of 
DM. 31.9% of prescription contained sulphonylurea with metformin which was 
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the highest percentage among the oral combination therapy. The least 
percentage of 0.3% were prescribed sulphonylurea with thiazolidinediones.    
 Study undertaken by Rajeshwari et al.53 on DUS of antidiabetic drugs 
noted that majority of patients were on combination therapy of 71.87% and 
the remaining on monotherapy. Metformin was the most frequently utilized 
antidiabetic medication as monotherapy in 78.12% and the least was 
gliclazide in 6.25% of the study population. 
In a cross sectional study conducted by Upadhyay et al.54 observed 
that 51.27% of the diabetic patients were prescribed with biguanides. 
 Utilization of sulphonylurea group of agents showed a decreasing trend 
with a dramatic increase in prescription of biguanides in a study designed by 
Yahaya et al.55 biguanides, sulphonylurea and α glucosidase inhibitors were 
prescribed in 51.3%, 48.5% and 0.2% respectively. 
Study of utilization pattern by Abdul et al.56 classified the antidiabetic 
medication prescribed as metformin (32%), glibenclamide (24.6%) and insulin 
(3.4%). Combination drug therapy prescribed were metformin with 
glibenclamide (28.6%), metformin with insulin (6.9%), metformin with 
glibenclamide and insulin (3%) and glibenclamide with insulin (1.5%). 
Metformin was the monotherapy of choice prescribed in 32.2% in a 
study conducted by Kannan et al.57 glimepiride was the sulphonylurea of 
choice as combination therapy with metformin in the same study.  
Drug prescribing pattern for diabetes in a tertiary care hospital studied 
by Akila et al.58 showed a drastic decline in glibenclamide prescription. 
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Metformin was the predominantly prescribed oral hypoglycemic agent both as 
monotherapy and combination therapy. There   was a significant increase in 
the use of new antidiabetic agents like thiazolidinediones, α glucosidase 
inhibitor and DPP-4 inhibitor.    
Lisha et al.59 studied metformin to be the drug of choice as mono 
therapy and as combination therapy. Glipizide was found to dominate among 
the sulphonylurea. Pioglitazone was prescribed as combination therapy in few 
patients. Human insulin was the commonly prescribed insulin preparation.           
In a prospective observational study conducted by Sarumathy et al.60 
antidiabetic were prescribed as monotherapy. Biguanides in 11.5% was found 
to be the most commonly prescribed antidiabetic drugs and least being α-
glucosidase inhibitors in 6% of the study subjects. 20.6% were treated with 
combination of metformin and glibenclamide. Pre-mixed insulin (Human 
mixtard) was the commonly administered insulin preparation.        
Jimoh et al.61 study on pattern of antidiabetic use has shown the 
predominance of type 2 DM. Patients on combination therapy was higher. 
Insulin was frequently utilized antidiabetic medication among monotherapy.    
In a cross sectional study conducted in North India by Sharma et al.62 
observed that the most prescribed antidiabetic drug was sulphonylurea 
(50.4%), followed by biguanides (46.6%) . Among sulphonylurea, glimepiride 
was the most prescribed and the least was glipizide.   
Antidiabetic prescription evaluation study done by Acharya et al.63 
showed metformin to be the most frequently prescribed (40.45%) antidiabetic 
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drugs followed by glimepiride (28.39%), insulin(11.32%), voglibose(9.46%), 
pioglitazone(5.38%), repaglinide(1.86%), sitagliptin(1.30%), vidagliptin(0.37%) 
and glibenclamide(0.19%). 
DUS in Tenali by Kumar KS et al.64 showed insulin (65%) to be the 
most commonly utilized antidiabetic medication. Other drugs prescribed were 
metformin (54.2%), glimepiride (21%), glibenclamide (10%), glipizide (6.7%) 
and gliclazide (2.5%). Most commonly prescribed two drug combination 
therapies were glimepiride with pioglitazone (42.5%), insulin with metformin 
(16.6%), glimepiride with metformin (10%), glibenclamide with metformin 
(8.3%), glipizide with metformin (3.3%) and insulin with glimepiride (2.5%). 
Three drug combinations prescribed were insulin with glimepiride, metformin 
(8.3%) and glimepiride with pioglitazone, metformin (6.6%).   
Study on prescribing pattern done by Shahir et al.65 found out that 
percentage of participant receiving antidiabetic medicine according to the 
gender was 54.83% in male and 45.16% in female patient. The drugs 
prescribed were sulphonylurea (26.74%), glimepiride with metformin 
(18.60%), pioglitazone (13.56%), insulin (5.81%), insulin and other oral 
antidiabetic drugs (5.81%), glimepiride with pioglitazone, metformin (2.32%), 
glimepiride with pioglitazone (1.16%), sitagliptin (0.77%) and acarbose 
(0.77%). Insulin preparation used were human mixtard 30/70 penfil (30), 
human regular insulin (actrapid penfil) (10), NPH (isophane) pen (6), and 
insulin glargine pen (2). 
Patel et al.66 tabulated the antidiabetic medication prescribed as 
biguanides (87.7%), sulphonylurea (68.4%), insulin (22.8%), α glucosidase 
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inhibitors (21.1%), DPP-4 inhibitors (10.5%) and thiazolidinediones (10.5%).  
Antidiabetic combination drugs prescribed were glimepiride with metformin 
(50%), metformin with voglibose (7.02%), glimepiride with metformin, 
pioglitazone (7.02%), metformin with vildagliptin (3.51%), glibenclamide with 
metformin (1.75%) and sitagliptin with metformin (1.75%). Antidiabetic 
medication was prescribed as monotherapy (81.58%), two drug combination 
(65.78%) and three drug combination (7.02%). Classes of drugs prescribed 
were biguanides (40.35%), sulphonylurea (12.28%), α glucosidase inhibitors 
(16.67%), DPP-4 inhibitors (5.26%) and thiazolidinediones (7.02%). Average 
number of drugs prescribed per prescription was 7.58 ± 2.49. Percentage of 
drugs prescribed by generic name was 3.94%.    
Jhaveri et al.67 described antidiabetic utilization in geriatric population. 
Among the various drugs prescribed, antidiabetic medication included plain 
insulin (13.2%) and metformin (5.2%).   
Observational study conducted in Eastern Nepal by Das et al.68 in 2011 
analysed the pattern of antidiabetic medication. Percentage of classes of 
drugs prescribed were biguanides (24.5%), sulphonylurea (19.9%), 
thiazolidinediones (3.6%) and insulin (2.5%). Number of drugs prescribed 
from each class were metformin (69), glimepiride (53), pioglitazone (10), 
soluble with isophane insulin (5), glipizide (3) and glargine insulin (2). 
Guidoni et al.69 analyzed the prescription pattern based on anatomical 
therapeutic group. Antidiabetic drugs prescribed as monotherapy were insulin 
(3.4%), glibenclamide (24.6%) and metformin (32%). Combination therapy 
prescribed were metformin with glibenclamide (28.6%), glibenclamide with 
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insulin (1.5%), metformin with insulin (6.9%) and metformin with glibenclamide 
and insulin (3.0%).   
Kumar et al.70 recorded the prescribing pattern in predesigned form 
and analysis revealed percentage of drugs prescribed as monotherapy were 
sulphonylurea (26.99%), insulin (17.18%), biguanides (14.1%) and α-
glucosidase inhibitors (0.61%). As combination therapy drugs prescribed were 
metformin with human insulin (15.95%), human insulin (short acting and long 
acting), metformin with glibenclamide (5.52%), glimepiride with human insulin 
(3.68%) and metformin with glimepiride (1.84%). Drugs prescribed by generic 
name were minimum (14.59%) while maximum prescribed by brand name 
(85.08%). 
Investigation of in-patient prescribing pattern of oral antidiabetic drugs 
in a tertiary care hospital by Himanshu et al.71 declared the gender wise 
distribution as 57.5% in male and 42.5% in female. Drugs prescribed were 
metformin (43.8%), glimepiride (13.9%), glibenclamide (7.3%), metformin with 
glibenclamide (7.3%), metformin with gliclazide (5.8%), pioglitazone (5.1%), 
glipizide (2.9%), metformin with pioglitazone (1.5%) followed by metformin 
with glimepiride and pioglitazone (1.5%).            
Taskeen et al.72 study on rational drug prescribing pattern in geriatric 
patient, the most commonly prescribed drugs were antidiabetic medication 
(15.58%). Metformin was prescribed to maximum number of patient.    
In Willey et al.73 retrospective study, antidiabetic medication given as 
monotherapy were sulphonylurea (804), metformin (230), insulin (107) and 
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sulphonylurea with metformin (428), insulin with metformin (42), 
sulphonylurea with thiazolidinediones (41), metformin with thiazolidinediones 
(13), insulin with sulphonylurea (8), insulin with thiazolidinediones (7), 
sulphonylurea with α glucosidase inhibitor (2), sulphonylurea with other 
sulphonylurea (1) and metformin with meglitinide (1). Distribution of three drug 
combination were sulphonylurea, metformin with thiazolidinediones (52), two 
sulphonylurea with metformin (3) and metformin with thiazolidinediones (1).     
Adla et al.74 study showed metformin use in 68.75% and glibenclamide 
with metformin in the remaining of the diabetic patients studied during the 
analysis. 
Gulam et al.75 assessed oral hypoglycemic drug utilization in type 2 
DM. Percentage of utilization pattern of antidiabetic drugs were metformin 
(34.5%), glimepiride (26.3%), pioglitazone (19.1%), miglitol (6.20%), 
vildagliptin (4.59%), gliclazide (2.2%), acarbose (1.93), voglibose (1.93%), 
sitagliptin (1.44%), rosiglitazone (1.2%) and glipizide (0.5%). Percentages of 
patients receiving antidiabetics as monotherapy were maximum with 
biguanides (10.9%) and minimum with thiazolidinediones (1.1%) and DPP4 
inhibitors (1.1%). Maximum percentage encountered with various of patients 
receiving as 2 drug therapy were glimepiride with metformin (13.04 %), as 3 
drug therapy were glimepiride with metformin, pioglitazone (23.9%) and as 4 
drug therapy were glimepiride with metformin, pioglitazone, miglitol (8.2%). 
Rajkumar et al.76 observed the drug use pattern among type 2 
diabetics  which was found to be more among females (51.66%) than males 
(48.34%) and type 1 includes 66.67% in male and 33.33% in female. 
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Prescribed pattern of different antidiabetic drugs as monotherapy in 
percentage were glimepiride (36.8%), metformin (31.4%), pioglitazone (8%), 
insulin (7.8%), gliclazide (4.8%), voglibose (4%) and vildagliptin (1.6%). 
Metformin was given as a combination therapy with glimepiride (6.4%), 
gliclazide (3.2%) and pioglitazone (0.8%). A combination of glimepiride, 
metformin and pioglitazone was given in 4% of the patient. 
In a cross sectional retrospective study done by Hasniza et al.77 
revealed that insulin was the most common antidiabetic prescribed. The most 
common combination therapy was oral hypoglycemic with insulin (17.5%). 
Most frequently used oral antidiabetic were biguanides, sulphonylurea 
followed by acarbose and sitagliptin. 
Prescription in type 2 DM in tertiary care hospital by Sharma et al.78 
studied that 77% of the drugs were prescribed as monotherapy. Metformin 
was advised as monotherapy in 31.72% of the patients. Other drugs 
prescribed as monotherapy were glimepiride, glibenclamide, voglibose, 
pioglitazone, insulin, sitagliptin and vildagliptin.   
Sutharson et al.79 gave details on percentage of drugs prescribed at 
diabetic OPD as glibenclamide (47.4%), metformin (38.1%), glipizide (24.9%), 
lente insulin (5.6%), insulin porcine mixture (5.5%), regular insulin (5.2%) and 
tolbutamide (1.4%).   
Okonta et al.80 conducted a study to evaluate prescription pattern of 
antidiabetic and antihypertensive medication in Nigeria. Patients name was 
mentioned only in 93.4% of the prescription. Gender wise distribution of drug 
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(55.1%) than males (44.9%).  Drugs prescribed by generic name were 38.7% 
and by trade name were 61.3%. Classes of antidiabetic drugs prescribed 
were biguanides (42.3%), sulphonylurea (26.2%), combination of 
sulphonylurea with biguanides (20.2%), insulin (10.7%) and thiazolidinediones 
(0.6%).    
A study done on prescribing pattern of antidiabetic drugs by 
Vengurlekar et al.81 categorised use of prescribed drugs  as biguanides 
(27%), sulphonylurea (22.60), glitazones (13.90%), miglitol (8.69%) and 
insulin (4.5%). Most commonly prescribed combination therapy was 
metformin with glimepiride (20.86%) followed by pioglitazone with glimepiride 
(4.34%) and pioglitazone with metformin (2.6%). 51 to 60 year of age were 
commonly affected followed by 41 to 50 years. Majority of affected population 
were male (66.36%) and   was lesser among females (33.64%).            
Alam et al.82 study on drug utilization pattern in New Delhi identified 
that 37% of the diabetic patients were advocated with metformin, 31.9% with 
sulphonylurea, 24.8% with thiazolidinediones and α glucosidase inhibitors in 
6.3% as monotherapy. 
Dhwani et al.83 studies on prescribing trends in diabetic patients 
analyzed 492 data out of which 67.88% were males and 32.11% were 
females. Percentage of antidiabetic medication prescribed were metformin 
76%, insulin 35%, gliclazide 31.50%, pioglitazone 25.60%, glimepiride 
24.60%, acarbose 16.10%, glipizide 13.40%, rosiglitazone 10.20% and 
glibenclamide 4.70%. Combination of antidiabetic prescribed were insulin with 
metformin (12.8%), metformin with glimepiride (8.7%), metformin with 
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gliclazide, pioglitazone (7.9%), insulin with gliclazide (5.9%) and gliclazide 
with metformin (5.5%).  
In a comparative study of drug use pattern conducted by Garg et al.84 
revealed that 79.6% in retrospective and 43.4% in prospective were found to 
be treated with antidiabetic drugs. The most commonly prescribed drugs were 
sulphonylurea (39.7% in retrospective and 22.8% in prospective) followed by 
biguanides (21.5% in retrospective and 13% in prospective) and insulin (9.2% 
in retrospective and 4.8% in prospective).   
Suleiman et al.85 prescription analysis in Sharjah General hospital 
showed that among the various drugs prescribed 19.49% were antidiabetic 
drugs. Most commonly prescribed antidiabetic drugs were metformin 
(58.71%) and the least were glimepiride (4.98%). Gliclazide were prescribed 
in 34.33% of the analysed data.    
A gender based antidiabetic survey done by Raj et al.86 revealed that 
type 2 DM predominate. Metformin was the preferred antidiabetic among 
monotherapy prescribed to 30% of the patients. Most frequently prescribed 
combination therapy was glibenclamide with metformin in 27%.    
Stavros et al.87 observed the antidiabetic drug treatment in Greek 
patients. Percentage of study population prescribed with oral antidiabetic 
drugs were 56.5% and 42.6% with insulin. Oral antidiabetic drugs prescribed 
were metformin (80.4%), DPP-4 inhibitor (34.5%), sulphonylurea (26.6%), 
thiazolidinediones (4.9%), GLP-1 agonist (3.8%), glinide (2.7%) and acarbose 
(2.2%). 
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Observation of prescription pattern by Yusefzadeh et al.88 revealed that 
biguanides (61.7%) was the most often prescribed antidiabetic medication. 
Other drugs prescribed less frequently were sulphonylurea (59.9%), α-
glucosidase inhibitors (4.5%), repaglinide (2.7%) and thiazolidinediones 
(0.7%). Insulin was given as monotherapy in 23.7% and as combination 
therapy with oral antidiabetic drugs in 6.8%. Oral antidiabetic medication as 
monotherapy was prescribed in 69.5%. Among the various classes of drugs 
metformin (61.7%) and glibenclamide (59.9%) were the most commonly 
prescribed antidiabetic drugs. 30.5% of the prescription included insulin 
preparation. Insulin preparation commonly prescribed were NPH with regular 
insulin (20.7%), NPH (4.5%), insulin aspart (3.6%), regular (0.9%), insulin 
glargine (0.6%), lansulin N (0.2%). Most frequently prescribed combination 
therapy were metformin with glibenclamide (41.5%). This study also identified 
the common co-morbid condition like hypertension, angina pectoris and 
hyperlipidemia to be associated with DM.  
Knox et al.89 study on antidiabetic drug utilization in pregnant women 
showed a steady increase in the use of metformin and sulphonylurea. Most 
commonly prescribed antidiabetic drugs were insulin, metformin, 
sulphonylurea and thiazolidinediones.    
Study about utilization pattern of antidiabetic medication was done by 
Dave et al.90 Oral antidiabetic drug prescribed as single and combination 
therapy were 14.83% and 68.82% respectively. Percentage of oral 
antidiabetic drugs in combination with insulin was 16.55%. Combination 
therapy prescribed were glipizide with metformin (38.42%), glipizide with 
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pioglitazone (3.45%), glipizide with pioglitazone (2.76%), metformin with 
glimepiride (2.76%), metformin with pioglitazone (1.38%), acarbose with 
glipizide and metformin (1.38%) and gliclazide with pioglitazone (1.38%). 
Other less commonly prescribed antidiabetic combination therapy (1.72%) 
were glipizide either with repaglinide, rosiglitazone, metformin or glimepiride 
and pioglitazone with glimepiride.  
Outpatient utilization of antidiabetic drugs was studied by Adibe et al.91
Antidiabetic drugs frequently prescribed were metformin (38.6%), 
glibenclamide (27.9%), chlorpropamide (13.4%), fast acting insulin (9.9%), 
intermediate-acting insulin (6.8%) and rosiglitazone (4.4%). 
A prospective study on drug utilization of oral hypoglycemic therapy in 
type 2 DM was done by Khan et al.92 Classes of antidiabetic drug prescribed 
were biguanides in 34.5%, sulphonylurea in 28.9%, thiazolidinediones in 
20.3%, α glucosidase inhibitors in 10.14% and DPP-4 inhibitors in 6.03%. 
Percentage of individual drugs prescribed were metformin in 34.5%, 
glimepiride in 26.3%, pioglitazone in 19.1%, miglitol in 6.20%, vildagliptin in 
4.59%, gliclazide in 2.2%, voglibose in 1.93%, acarbose in 1.93%, sitagliptin 
in 1.44%, rosiglitazone in 1.2% and glipizide in 0.5%. 
Abassi et al93 study on current prescribing pattern of antidiabetic drugs 
revealed that metformin was the most frequently advocated by the treating 
physician. The other drugs prescribed were sulphonylurea in 30.68%, insulin 
in 21.96%, thiazolidinediones in 9.12% and DPP-4 inhibitors in 1.65%.  
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4.6. Studies related to adverse drug reactions of antidiabetic drugs: 
Pharmacovigilance study done by Himanshu et al.46 identified 122 
reports of ADRs due to different groups of drugs out of which 10.7% were due 
to antidiabetic therapy.   
Saravanan et al.94 identified that male were predominantly reported 
ADRs due to administration of antidiabetic medications. The above study 
reported hypoglycemia, vomiting, giddiness, abdominal distension, diarrhea, 
sweating, edema, gastric irritation and headache in the study population. The 
same study also revealed that the incidence of adverse drug reactions were in 
the higher side in patients treated with glimepiride compared to metformin, 
pioglitazone and   combination of glimepiride with metformin.    
Monitoring of ADRs in a tertiary care teaching hospital by Kathiria et 
al.95 identified that hypoglycemia due to insulin was 3.33%. Among the 
various ADRs reported 13.33% were due to antidiabetic medication.   
Sharma et al.96 analysed 465 vigiflow data on ADR associated with 
antidiabetic medication and identified the gender distribution to be 273 in male 
and 182 in female. Number of patients reported ADR were 218 with insulin, 74 
with metformin, 41 with glimepiride, 36 with glibenclamide, 33 with glitazone, 
22 with glipizide, 5 with acarbose, 2 with human actrapid and 2 with DPP-4 
inhibitors. Other system affected following use of antidiabetic were classified 
as metabolic and nutritional in 279, gastrointestinal system disorders in 78, 
central and peripheral nervous system disorders in 40, skin and appendage 
disorder in 30, general disorder in 16, psychiatric disorder in 4, respiratory 
system disorder in 2, special senses in 2, heart rate and rhythm disorder in 2, 61 | P a g e
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vascular disorder in 2, cardiovascular disorder in 2, liver and biliary system 
disorder in 1 and vision disorder in 1.  
An analysis was done on medication use leading to emergency 
department visits for ADR in older adults by Daniel et al.97 Most common 
antidiabetic medication implicated to cause ADR in decreasing order were 
13% with insulin, 2.3% with metformin, 2.2% with glyburide and 1.5% with 
glipizide.  
Budnitz et al.98 studied medication use leading to emergency 
department visits due to adverse drug events in older adults. Number of 
patients reported with ADR due to DM treatment was 616 with Insulin, 103 
with metformin, 98 with glyburide and 57 with glipizide. 
Hypoglycemia was the frequently noticed ADR in 18 diabetic patient 
during a study on adverse effects of antidiabetic medication by William et al.99
Patient encountered with hypoglycemic episode were on sulphonylurea. 
4.7. Studies related to pharmacoeconomic study of antidiabetic drugs: 
In a pharmacoeconomic analysis conducted by Upadhyay et al.54 found 
out that cost per prescription for insulin was 41.07% and it was 32.60% for 
biguanides of the total cost encountered.  
In a study conducted by Kannan et al.57 average cost of therapy per 
prescription for one month was Rs 783.55. Cost of antidiabetic therapy for one 
month was less than Rs 600 in 79 prescriptions, Rs 601 to 1200 in 99, Rs 
1201 to 1800 in 19, Rs 1801 to 2400 in 4 and more than Rs 2401 in 1 
prescription.   
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In an observational study conducted by Sarumathy et al.60 the average 
prescription cost was Rs 65.26 per 5 days for treating DM.   
Jhaveri et al.67 did pharmacoeconomic analysis in geriatric population 
on antidiabetic therapy. Total cost of treatment was found to be 665. 
Pharmacoeconomic study of antidiabetic drugs was studied by Adibe et 
al.91 and showed that cost of DM therapy to be rosiglitazone = 160.7, fast 
acting insulin = 108, intermediate-acting Insulin = 98.5, metformin = 57.1, 
chlorpropamide = 26.3 and glibenclamide = 10.7.  
Asseffa et al.100 analyzed the cost of therapy with antidiabetic 
medication. Percentages of total drug cost were 88.19 with Insulin, 5.26 with 
metformin and 0.97 with glibenclamide. 
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5. Materials and methods:
5.1. Study design: 
 This study was designed a cross sectional study. 
5.2. Study setting:  
This study was conducted at OPD of Medicine, Sree Mookambika 
Institute of Medical Sciences,     Kulasekharam, Kanyakumari District, 
Tamil Nadu. 
5.3. Study period: 
     This study was done during the period August 2013 to August 
2014. 
5.4. Inclusion criteria: 
1. DM patients attending the Medicine OPD
2. DM patients with or without other co-morbid conditions.
3. Both gender affected with DM
4. Patients with type 1 or type 2 DM
5.5. Exclusion criteria: 
     Patients attending the Medicine OPD for re-fill of antidiabetic drugs 
who have been given the recruitment number 
5.6. Parameters: 
i. Study participants receiving antidiabetic drugs as monotherapy
ii. Study participants receiving antidiabetic drugs as combination
therapy 64 | P a g e
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iii. Study participants receiving antidiabetic drugs as combination
therapy
iv. Classes of antidiabetic drugs with most expensive and least
expensive
v. Adverse drug reactions experienced in patients prescribed with
antidiabetic drugs
5.7. Institutional Human Ethics Committee Approval: 
      The study proposal was submitted to Institutional Human Ethics 
Committee (IHEC) of Sree Mookambika Institute of Medical Sciences 
(SMIMS), Kulasekharam, Kanyakumari District, Tamil Nadu for 
approval and the research proposal was approved by the IHEC of 
SMIMS with Ref. No. SMIMS/IHEC/2013/A/21. The certificate of 
approval for the same has been enclosed in annexure.  
5.8. Procedure: 
The study was conducted in collaboration with the Department of 
Medicine. Study subjects who were diabetic either with or without other 
co-morbid condition were recruited according to the inclusion and 
exclusion criteria from the Outpatient Department of Medicine. 
Informed written consent was obtained from each study subject. Details 
of each study subject was recorded in a predesigned case  record 
form. Prescribed antidiabetic drugs details including formulation, dose, 
frequency, duration, route of administration and whether taken before 
or after food was noted in the case record form. Cost of antidiabetic 
therapy for a period of one month was calculated. 
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Figure 5: Flow chart showing the methodology of the study 
Cross sectional study 
Study site: Outpatient department of Medicine, SMIMS, Kulasekharam 
Study period: From August 2013 to August 2014 
1. Drug utilization pattern of antidiabetic drugs 
Parameters studied 
i. Generic or Brand name 
ii. Monotherapy or combination therapy 
iii. Rational or Irrational 
2. Adverse drug reactions of antidiabetic drugs 
Assessment of ADRs using: 
i. WHO scale 
ii. Naranjo scale 
iii. Modified Schumock and Thornton 
iv. Modified Hartwig and Siegel 
3. Cost of therapy per month (INR) 
Institutional Human Ethics Committee Approval 
Inclusion criteria 
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Study subjects were enquired regarding presence of other co-morbid 
condition and if so drugs prescribed for the same was noted. Enrolled 
study participants were interviewed regarding experience of any 
adverse effect following initiation of antidiabetic therapy. If yes, ADR 
experience details will be filled up in the CDSCO ADR form. 
5.9. Method of analysis: 
Data obtained from case record form will be presented as: 
i. Percentage of study participants receiving antidiabetic drugs as
monotherapy.
ii. Percentage of study participants receiving antidiabetic drugs as
combination therapy.
iii. Percentage of participants receiving different
 Classes of antidiabetic drugs like sulphonylureas, biguanides,
thiazolidinediones
 Classes of antidiabetic drugs which will be more expensive and least
expensive
 Causality assessment of adverse drug reactions reported in patients
prescribed with antidiabetic drugs by using
i. WHO Causality assessment
ii. Naranjo algorithm
iii. Modified Schumock and Thornton
iv. Modified Hartwig and Siegel
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i. WHO Causality assessment101
This assessment scale was put forth by the World Health organisation 
collaborating centre for International Drug Monitoring, the Uppsala Monitoring 
centre (WHO-UMC). Suspected adverse drug reactions due to drugs are 
combined assessment taking the case history and quality of documentation of 
observation. 
Assessment criteria Causality category 
 Adverse event or laboratory abnormality
occurring in a plausible time relationship to
drug intake
 Cannot be explained by disease or other
drugs
 Response to withdrawal
 Satisfactory rechallenge
Certain 
 Adverse event or laboratory abnormality
occurring in a plausible time relationship to
drug intake
 Cannot be explained by disease or other
drugs
 Response to withdrawal
 Rechallenge is not required
Probable/Likely 
 Adverse event or laboratory abnormality
occurring in a plausible time relationship to
drug intake
 Can also be explained by concurrent disease
or other drugs
 Lack information on drug withdrawal
Possible 
Table No 7: WHO causality assessment scale 
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 Adverse event or laboratory abnormality
occurring in a temporal relationship to  drug
intake
 Causal relationship is improbable
Unlikely 
 Adverse event or laboratory abnormality
reported
 More data essential for proper assessment
Conditional/ 
Unclassified 
 Adverse event reported
cannot be assessed because of-
 Insufficient information or
 Contradictory
Unassessible/ 
Unclassifiable 
ii. Naranjo algorithm102
Naranjo Probability Scale assesses unexpected ADRs. It is helpful for 
evaluators with little experience.  
 
Questions Yes No Do not know 
Any previous conclusive report on this 
reaction? +1 0 0 
Did the adverse event appeared soon after the 
administration of suspected drug? +2 -1 0 
Was there an improvement in adverse 
reaction after the drug was discontinued or 
when specific antagonist was administered? +1 0 0 
When the drug was discontinued did the 
adverse reaction reappear? +2 -1 0 
Table No 8: Naranjo algorithm scale 
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Is there any alternative reason that could 
have caused the reaction? 
 
 
-1 
 
+2 
 
0 
Whether reaction reappeared when a placebo 
was given? 
 
 
-1 
 
+1 
 
0 
Whether drug was detected in the blood in a 
concentration known to be toxic? 
 
+1 
 
0 
 
0 
Severity of reaction – is it more severe when 
the dose was increased or less severe when 
the dose was decreased? 
 
 
+1 
 
 
0 
 
 
0 
Did the patient experience similar reaction to 
the same or similar drugs in any previous 
exposure?  
 
 
+1 
 
 
0 
 
 
0 
Was the adverse event confirmed by any 
objective evidence? 
 
+1 
 
0 
 
0 
 
Category is defined by calculating the total score from this table as: 
 
 
 
 
iii. Modified Schumock and Thornton102,103 
Define various criteria to determine preventability of an ADR.  
 
1 to 4 :Possible 
5 to 8 :Probable 
More than 9 :Definite 
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Section A 
1. History of allergy or previous reaction to the drug
2. Inappropriate drug for patient’s clinical condition
3. Dose, route or frequency of drug administration inappropriate for
the patient’s age, weight or disease state
4. Documentation of toxic serum blood concentration
5. Treatment known for the adverse drug reaction
Answering yes to one or more of the above questions implies that an ADR is 
Definitely preventable. If answer is no then proceed to next section. 
Section B 
1. Required therapeutic drug monitoring not performed
2. Any drug interaction involved in the ADR
3. Poor compliance involved in the ADR
4. Preventive measures not prescribed or administered to the patient
Answering yes to one or more of the above questions implies that an ADR is 
Probably preventable. If answer is no then proceed to next section. 
Section C 
If answers are negative to section A and B then the ADR is Not preventable 
iv. Modified Hartwig and Siegel102,103
Severity of ADR can be assessed using this scale. 
ADR is Mild if it requires: 
 Level 1: no change in treatment with the suspected drug (or)
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 Level 2: suspected drug to be withheld or changed, no antidote
required, no increase in length of stay
ADR is Moderate: 
 Level 3: If it requires suspected drug to be withheld or changed,
antidote or other treatment is required, no increase in length of
stay (or)
 Level 4(a): Any level 3 with increase in length of stay by at least
one day (or)
 Level 4(b): If ADR is the reason for admission
ADR is Severe: 
 Level 5: Any level 4 that requires intensive care treatment (or)
 Level 6: Permanent harm to the patient (or)
 Level 7: Directly or Indirectly leads to death of the patient
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6. Results: 
6.1. Demographic characteristics: 
      The demographic profile of 169 diabetic patients is given in table no 9.In 
the current study the age group commonly affected was found to be between 
the 61 to 70 years. Gender wise distribution of diabetic patients shows 
predominance among the female patient accounting 111 prescriptions and 
remaining being male. The mean weight of diabetic patients accounted during 
the study was 67.56 kg. Average height of the diabetic patients in this study 
was 155 cm. Body mass index was calculated as mean and was found to be 
27.82 kg/m2.     
6.2. Clinical presentation of diabetes mellitus: 
      Patients attending the diabetic OPD during the study period were with 
type 2 DM alone. Among them known case of DM were 146 and the newly 
diagnosed patients were 23 only as shown in table no 10. 
6.3. Co-morbid conditions associated with diabetes mellitus:   
      In this study systemic hypertension was the most frequently associated 
co-morbid condition as shown in table no 11. The other less common co-
morbid conditions were chronic obstructive pulmonary disease (COPD), 
dyslipidemia, thyroid disorder, benign prostatic hypertrophy (BPH), 
cardiovascular disorder and depression.  
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6.4. Antidiabetic drugs prescribed by generic name and brand name: 
      The pie diagram represented in figure 6 give details of antidiabetic drugs 
as prescribed by the physician. Out of 192 drugs prescribed, more percentage 
of drugs was prescribed by brand name and drugs prescribed by trade name 
were only 13%. 
6.5. Prescription as monotherapy and combination therapy: 
      Figure 7 depicts the prescribing of antidiabetic drugs as a single therapy 
or combination therapy. Managing DM with more than two drugs was 
advocated for 73% of the patients and the remaining being with one drug. 
6.6. Prescription as combination therapy: 
      Various numbers of drugs prescribed in combination therapy is shown in 
figure 8. Majority of patients were prescribed with 2 drug combination therapy 
and the remaining with 3 drugs and 4 drug combination therapies.  
6.7. Antidiabetic drugs prescribed as monotherapy: 
      Bar diagram in figure 9 depicts the drugs used as monotherapy. 
Frequently utilized drug as monotherapy was metformin, prescribed in 13 
patients. DM treated in 12 with insulin, 7 with pioglitazone, 4 with glimepiride, 
4 with voglibose, 3 with gliclazide and the rest with glibenclamide. 
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6.8. Antidiabetic drugs as 2 drug combination therapy: 
      Figure 10 representing the drugs used in 2 drug combination therapy. 80 
prescriptions contained a combination of glimepiride and metformin which is 
the highest among the 2 drug combination therapy. Metformin was prescribed 
with glipizide in 14, glibenclamide in 2, pioglitazone in 2, voglibose in 2 and 
insulin in 2. Pioglitazone was prescribed in two patients either with glimepiride 
or glipizide.    
6.9. Antidiabetic drugs as 3 drug combination therapy:  
      Glimepiride, metformin and pioglitazone was most commonly accounted in 
5 prescriptions among the 3 drug combination therapy. Glimepiride and 
metformin was prescribed with insulin in 3, voglibose in 2, acarbose in 2 and 
glibenclamide in 1. Pioglitazone and metformin was given in combination with 
sulphonylurea group (glibenclamide, glipizide or gliclazide) in 3 patients.  One 
prescription contained a combination of glimepiride, metformin and sitagliptin 
as viewed in figure 11. 
6.10. Adverse drug reaction reported due to antidiabetic drugs: 
      ADRs reported following treatment of DM with OHA and insulin is shown 
in figure 12.  ADRs shows hypoglycemia in 20, abdominal discomfort in 11, 
nausea with vomiting in 9, diarrhea in 7, edema in 6, headache in 6, myalgia 
in 5, rashes in 4, weight gain in 3, metallic taste in 3 and pruritis in 2. 
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6.11. ADRs reported with monotherapy: 
      Maximum of 14 ADRs were reported with insulin.  Drugs producing ADRs 
less frequently were thiazolidinediones, biguanides, sulphonylureas and alpha 
glucosidase inhibitors is represented in figure 13.  
6.12. ADRs with combination therapy: 
      Combination of drugs producing ADRs are shown in figure 14. 30 ADRs 
were reported due to combination antidiabetic therapy out of which 28 were 
due to sulphonylureas with biguanides and the remaining was due to 
sulphonylureas with biguanides and thiazolidinediones.  
6.13. Causality assessment using WHO scale: 
      64%of ADRs were probable, 16% possible, 7% conditional, 5% 
unclassifiable, 4% unlikely and rest certain as depicted in figure 15. 
6.14. Causality assessment using Naranjo algorithm scale: 
      Category of ADR according to the causative relationship to the drug 
administration is shown in the figure 16. Naranjo algorithm scoring 
categorised ADRs to be possible in 92% of the report. The remaining was 
probable and definite.  
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6.15. Preventability of ADR using Modified Schumock and Thornton 
scale: 
      ADR was found to be definitely preventable in 19% of the reports. It was 
only probably preventable in 18% and not preventable in the remaining as 
seen in figure 17. 
6.16. Severity of ADR using Modified Hartwig and Siegel scale: 
      Severities of ADRs reported were mild in 75% of the patients. Remaining 
was moderate and no severe ADRs were reported as shown in figure 18. 
6.17. Pharmacoeconomics of antidiabetic drugs as monotherapy: 
      Cost of therapy per month in Indian rupee (INR) for oral antidiabetic drugs 
prescribed in generic and brand name are individually represented as bar 
diagram in figure 19. Pharmacoeconomic evaluation shows that cost of 
therapy was higher with branded drugs while comparing with the generic 
equivalent. 
6.18. Pharmacoeconomics of antidiabetic therapy as fixed dose 
combination:  
      Fixed dose combination with 3 drugs was more expensive compared to 
combination with 2 drugs. Cost per month in INR for combination therapy 
used in this study is given in figure 20.   
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6.19. Pharmacoeconomics of insulin preparation: 
      Cost per unit of insulin preparation utilized in this study is represented as 
bar diagram in figure 21. 
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S. No Demographic characters Number  Percentage (%) 
1.  Age (years) 31 to 40 8 5 
  41 to 50 34 20 
  51 to 60 54 32 
  61 to 70 58 34 
  71 to 80 11 7 
  81 to 90 4 2 
2. Sex Male 58 34.31 
  Female 111 65.6 
3. Weight  (kg)  67.56±14.17*  
4. Height (cm)  155±0.04*  
5. BMI (kg/m2)  27.82±5.05*  
 BMI: Body mass index *Values are expressed in Mean±SD SD: Standard Deviation  
Table No. 9: Demographic profile of the diabetic patients on antidiabetic therapy  
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S. No Clinical presentation n % 
1. Type of DM Type 1 0 0 
  Type 2 169 100 
2. DM presented as Known case 146 86.39 
  Newly diagnosed 23 13.61 
    
n: Number %: Percentage 
Table No. 10: Distribution of patients according to clinical presentation  
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S. No Co-morbid condition n  % 
1. Systemic hypertension 62 71 
2. Chronic obstructive pulmonary disease (COPD) 7 8 
3. Systemic hypertension with COPD 6 7 
4. Dyslipidemia 3 4 
5. Hypothyroidism 3 4 
6. Benign prostatic hypertrophy 2 2 
7. Cardiovascular disorder 1 1 
8. Hyperthyroidism 1 1 
9. Systemic hypertension with dyslipidemia 1 1 
10. Depression 1 1 
    
Table No. 11: Number and percentage of co-morbid conditions associated with DM  
n: Number %: Percentage 
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167 (87%)
25 (13%)
Brand name Generic name
Figure-6: Pie diagram showing number of antidiabetic drugs prescribed by generic name and brand name  
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46 (27%)123 (73%)
Mono therapy Combination therapy
Figure-7: Pie diagram showing percentage of prescription of antidiabetic drugs as monotherapy and combination therapy  
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2 Drug3  Drug4 Drug
Figure-8: Pie diagram showing the percentage wise distribution of antidiabetic drugs as combination therapy  
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Figure-9: Bar diagram showing the number of prescriptions of antidiabetic drugs as monotherapy  
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Figure-10: Bar diagram showing the number of prescriptions of antidiabetic drugs as combination of 2 drugs  
86 | P a g e  
 
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5
3
2
2
1
1
1
1
1
0 1 2 3 4 5 6
Glimepiride + Metformin + Pioglitazone
Glimepiride + Metformin + Insulin 
Glimepiride + Metformin + Voglibose
Glimepiride + Metformin + Acarbose
Glimepiride + Glibenclamide + Metformin  
Glibenclamide + Metformin + Pioglitazone
Glipizide + Metformin + Pioglitazone
Gliclazide + Metformin + Pioglitazone 
Glimepiride + Metformin + Sitagliptin
Number of Prescriptions
Figure-11: Bar diagram showing the number of prescriptions of antidiabetic drugs as combination of 3 drugs  
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Figure-12: Bar diagram showing the adverse drug reactions reported due to antidiabetic drugs  
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Figure-13: Bar diagram showing ADRs reported by patients due to different classes of antidiabetic drugs as monotherapy  
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Figure-14: Bar diagram showing number of ADRs reported due to antidiabetic drugs prescribed as combination therapy  
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 Certain :Clinical event occurring in a plausible time relationship to drug administration, and cannot be explained by concurrent disease or other drugs or chemicals. Response to withdrawal of drug should be clinically plausible. Event must be definitive using a rechallenge procedure. Probable/Likely :Clinical event with a reasonable time sequence to administration of drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a clinically reasonable response on withdrawal.  Possible :Clinical event, with a reasonable time sequence to administration of drug, which could be explained by concurrent disease or other drugs or chemicals.  Unlikely :Clinical event occurring with a temporal relationship to drug administration which makes a causal relationship improbable, and in which other drugs, chemicals or underlying disease provide plausible explanations. Conditional/Unclassified :Clinical event reported as an adverse reaction, about which more data is essential for a proper assessment.  Unassessible/Unclassifiable :Report suggesting an adverse reaction, which cannot be judged because information is insufficient or contradictory. 
 
4%
64%
16%
4% 7% 5% CertainProbable / LikelyPossibleUnlikelyConditional / UnclassifiedUnassessible / Unclassifiable
Figure-15: Pie diagram showing the percentage wise distribution of causality assessment of adverse drug reactions due to antidiabetic drugs by WHO scale  
WHO scale 101 
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     Total score calculated defines this category as Possibly (1 to 4), Probably (5 to8) and Definitely (>9)  
Questions Yes No Do not know Was their previous conclusive report on this reaction?  +1 0 0 Did the adverse event appear after the suspected drug was administered? +2 -1 0 Did the adverse reaction improve when the drug was discontinued or specific antagonist was administered? +1 0 0 Did the adverse reaction reappear when the drug was               re-administered +2 -1 0 Are their alternative causes (other than the drug) that could have caused the reaction? -1 +2 0 Did the reaction reappear when a placebo was given? -1 +1 0 Was the drug detected in the blood (or other body fluids) in a concentration known to be toxic? +1 0 0 Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? +1 0 0 Did the patient have a similar reaction to the same or similar drugs in any previous exposure? +1 0 0 Was the event confirmed by objective evidence? +1 0 0    
 
92%
5% 3%
PossiblyProbablyDefinite
Figure-16: Pie diagram showing the percentage wise distribution of causative relationship of adverse drug reactions due to antidiabetic drugs by Naranjo Scale 
Naranjo Algorithm scale 102 
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i. Was there a history of allergy or previous reactions to the drug?ii. Was the drug involved inappropriate for the patient’s clinicalcondition?iii. Was the dose, route, or frequency of administration inappropriatefor the patient’s age, weight or disease state?iv. Was a toxic serum drug concentration (or laboratory monitoringtest) documented?v. Was there a known treatment for the adverse drug reaction?
Yes to one or more of the question ADR is Definitely preventable 
i. Was required therapeutic drug monitoring or other necessarylaboratory tests not performed?ii. Was a drug interaction involved in the ADR?iii. Was poor compliance involved in the ADR?iv. Were preventive measures not prescribed or administered to thepatient?
Yes to one or more of the question ADR is Probably  preventable 
If no to all the above questions ADR is Not preventable 
19%
18%63%
Definitely preventableProbably preventableNot preventable
Figure-17: Pie diagram showing the percentage wise distribution of preventability of adverse drug reactions due to antidiabetic drugs by Modified Schumock and Thornton scale 
Modified Schumock and Thornton scale 102,103 
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  Mild Level 1: Require no change in treatment with the suspected drug Level 2: Suspected drug discontinued or changed and no antidote is required   Moderate Level 3: Suspected drug discontinued and antidote or other treatment is required  Level 4(a): Level 3 that increase length of stay by atleast one day Level 4(b): ADR is the reason for admission  Severe Level 5: ADR that requires intensive medical care Level 6: ADR  causes permanent harm to patient Level 7: ADR either directly or indirectly leads to death of patient 
 
75%
25% Mild
Moderate
Figure-18: Pie diagram showing the percentage wise distribution of severity of adverse drug reactions due to antidiabetic drugs by Modified Hartwig and Siegel scale    
 Modified Hartwig and Siegel scale 102,103 
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Brand name Generic name Dibizide : Glipizide Daonil : Glibenclamide Cetapin  : Metformin Pioz : Pioglitazone Volibo : Voglibose Glimy : Glimepiride Diamicron  : Gliclazide Glucobay : Acarbose  Sitagliptin 
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Figure-19: Bar diagram showing cost of therapy (INR) per month for drugs prescribed as monotherapy     
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Brand name Generic name Glynase MF : Glipizide + Metformin K-Gem : Gliclazide + Metformin Daonil M : Glibenclamide + Metformin Glimy M : Glimepiride + Metformin Triglycomet : Glibenclamide + Metformin + Pioglitazone Trigulin : Glimepiride + Metformin + Pioglitazone 
Glynase MF
K-Gem
Daonil M
Glimy M
Triglycomet 
Trigulin 
64.08
126
179.4
222.72
299.76
467.4
Cost/month (INR)
Figure-20: Bar diagram showing cost of therapy (INR) per month for drugs prescribed as combination therapy 
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Brand name Generic name Huminsulin R : Regular insulin Huminsulin 30/70 : Isophane 70% + Soluble 30% Human mixtard : Isophane 70% + Biphasic 30% Lupisulin R : Regular insulin 
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0.42
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Human mixtard 
Human insulin 30/70
Cost/unit (INR)
Figure-21: Bar diagram showing cost of therapy (INR) per unit of various insulin preparations prescribed     
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7. Discussion: 
The present study was done to establish the current trend in the 
prescription pattern and adverse drug reaction profile of antidiabetic drugs in 
the outpatient department of Medicine, Sree Mookambika Institute of Medical 
Sciences, Kulasekharam, Kanyakumari district. This study has shown the 
prescription pattern of antidiabetic drugs including rationality in this part of 
south India.  Drug utilization study can improve the quality of treatment by 
managing this non communicable disease with a cost effective drug 
prescribed in generic name having tolerable adverse effects. Adverse drug 
reaction monitoring is still in the developmental stage in India and hence 
adverse drug reaction monitoring can help the health care professionals to 
deliver the drug effectively to the community.  
This study gave information regarding the frequency of prescription of 
anti diabetic medication which was higher in women than in men. This is 
found to be similar to the results obtained from previous studies done by 
Kumar et al.70 
Obesity and lack of physical activity plays an important role in the 
development of DM which can further complicate the condition and diminishes 
the response to treatment. Body mass index in men and women were 28.01 
kg/m2 and 27.82 kg/m2 respectively.  Average BMI of male and female were 
37 and 26 respectively in a study conducted by Akila et al.58   
In this study there were no patients diagnosed with type 1 DM and all 
the patients were either known case or newly diagnosed with type 2 DM. In a 
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DM were 98.4%. A study by Abdi et al.104 identified that the percentage of 
patients with type1 and type 2 DM were 2.28% and 97.71% respectively.   
 
Gender Kumar et al.70 Our study 
Male 48.6% 34.31% 
Female 51.4% 65.6% 
BMI (kg/m2) Akila et al.58 Our study 
Male  37 28.01 
Female 26 27.82 
Type of DM Sutharson et al.79 Our study 
Type 1 1.6% 0% 
Type 2 98.4% 100% 
Clinical presentation Akila et al.58 Our study 
New 3.15% 13.6% 
Known case 96.85% 86.39% 
Number of drugs  Akila et al.58 Our study 
Monotherapy 3.15% 27% 
Combination therapy 96.85% 73% 
Drug of choice Shahir et al.65 Our study 
Monotherapy Sulphonylurea 26.74% Metformin  28.26% 
New drugs Akila et al.58 Our study 
Thiazolidinediones 8.31% 15.21% 
      
BMI: Body mass index  
Table No 12: Comparison of results with other studies 
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Total of 169 prescriptions were analyzed during the study period out of 
which 23 (13.6%) were for newly diagnosed while 146 (86.39%) were for 
known cases of DM. This was comparable with the study conducted by Akila 
et al.58 
In this study there was a marked decrease in the prescription of drugs 
by generic name. Drugs prescribed by brand name and generic name were 
167 (87%) and 25 (13%) respectively. This observation was similar to the 
previous study reported by Acharya et al.63 
In our study 73% of the prescriptions were as combination therapy and 
27% as monotherapy. There was a decrease in the use of combination 
therapy compared to the previous study done by Akila et al.58 Metformin was 
the most frequently prescribed monotherapy in our study. In previous study 
done by Shahir et al.65 sulphonylurea was the most commonly prescribed 
class of drug as monotherapy. Switching over to biguanides is a changing 
trend in the utilization of antidiabetic medication. In our study following 
biguanides, insulin was used as a single drug to control hyperglycemia. Study 
done by Abdi et al showed a predominant use of parenteral Insulin instead of 
oral hypoglycemics.104 In the present study there is a marked increase in the 
use of thiazolidinediones compared to a study done by Akila et al.58 α- 
glucosidase inhibitors were also used in few prescription. Utilization of 
sulphonylurea as monotherapy has decreased while comparing with study 
done earlier by Acharya et al.63  
In this cross sectional study biguanides was one of the drug utilized in 
combination therapy. Sulphonylureas were more frequently prescribed along 
with metformin. Among the sulphonylureas, glimepiride was most commonly 100 | P a g e  
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used followed by glipizide. Glibenclamide was the most commonly prescribed 
sulphonylureas in the year 2003 by Sutharson et al.79 This gradual 
changeover may be due to decrease in the incidence of hypoglycemic 
episodes. In our study pioglitazone and voglibose were the newer drugs 
included in fewer prescriptions. Voglibose has a very good control over post 
prandial hyperglycemia which is an important contributor in development of 
microvascular complication.7    
In this current study, prescriptions containing 3 drug combination 
therapies were advocated in 10.05% of cases. α-glucosidase inhibitors 
voglibose, acarbose and DPP-4 inhibitors sitagliptin were the newer drugs 
prescribed in few patients during the analysis of prescription pattern in our 
study. 
When drug introduced to the heterogenous population following 
different phases of clinical trial, ADRs not identified earlier may become 
apparent. Pharmacovigilance plays a vital role in ensuring effective therapy 
with minimal adverse effects thereby protecting the public.103        
In the current study hypoglycemia was the most commonly 
experienced ADR by the diabetic patients. Increased report of hypoglycemia 
could be due to inappropriate intake of drugs, inappropriate instructions 
followed or inappropriate intake of food by the patients. Other non 
pharmacological factors contributing to development of hypoglycemia may be 
stress and infections.23 In this study the second most common ADR reported 
were gastrointestinal disturbances which is again in accordance with the 
previous study done by Saravanan et al.94      
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Assessment of ADRs helps in understanding the relationship of drug 
and the adverse effect, severity and preventability of the reactions reported. 
This can gain confidence and improve the adherence to the treatment given. 
Our study showed that 64% of the ADRs were probable by using WHO 
causality assessment scale since the effect developed soon after the 
administration of drug and not due to concurrent disease or other drugs. 92% 
of the ADRs scored 1 to 4 by using Naranjo algorithm scale and hence 
categorised to be possible. Most of the ADRs were not preventable (63%) as 
per modified Schumock and Thornton preventability scale.  Remaining ADRs 
were either probably or definitely preventable. Hence appropriate dose 
according to the patient’s requirement and appropriate instructions by the 
treating physician can prevent the ADRs. During the study no serious adverse 
drug reactions was reported. Most of the ADRs were mild to moderate in 
degree of severity as per modified Hartwig and Siegel scale. 
Prescription pattern contribute to the adherence to medication. This is 
more important in DM since it requires lifelong management. Adherence to 
the prescribed drug depends on cost effective drug with least adverse effect.75 
The least expensive preparation in our study was metformin and sitagliptin 
being the most expensive.  
While prescribing drugs for other co-morbid conditions, importance 
must be given while choosing drug. In this study systemic hypertension was 
the most common co-morbid conditions seen in the diabetic patients. COPD, 
dyslipidemia, thyroid disorder, cardiovascular disorder, benign prostatic 
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hypertrophy and depression were the other frequently observed co-morbid 
conditions.             
Rational prescription includes prescribing medication appropriately 
considering the safety profile and cost effectiveness of the prescribed drug.     
Appropriate and effective monitoring of ADR is the best way to safeguard the 
public. In a country like India with varied socioeconomic status, it is important 
to have a vigilant Pharmacovigilance programme. Management of DM 
rationally can improve adherence to therapy, minimise adverse effects and 
prolong the time for development of microvascular and macrovascular 
complication thereby effectively reducing the morbidity and mortality. 
Limitations of our study were socioeconomic state of the diabetic 
patients was not analyzed and glycemic control was not assessed. The 
availability of drugs in the hospital and the intake by the patients in the various 
age groups would have been a better method of DUS. 
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8. Conclusion:           
In cross sectional study conducted during the period of August 2013 to 
August 2014 to evaluate the drug utilization pattern of antidiabetic drugs found 
that the 73% of drugs prescriptions were by monotherapy and 23% by 
combination therapy and all were found to be rational. The study also showed 
that the 86.98% of prescriptions were by brand names and rest were by 
generic names. The pharmacoeconomics of the antidiabetic drugs prescribed 
in the study revealed that glibenclamide was the least expensive and 
sitagliptin as the most expensive drugs prescribed as monotherapy and in the 
combination therapy the least expensive was glipizide with metformin and 
most expensive was the combinations of glimepiride, metformin and 
pioglitazone.      
In this study the ADRs were found probable (64%), possible (16%), 
conditional (7%), unclassifiable (5%), certain (4%) and unlikely (4%) by using   
WHO causality assessment scale. By using Naranjo algorithm scale it was 
found that ADRs were possible in 92%, probable in 5% and definite in 3% of 
cases. Modified Schumock and Thornton scale for preventability of ADRs 
showed that ADRs were not preventable in 63%, definitely preventable in 19% 
and probably preventable in 18% of cases. Modified Hartwig and Siegel scale 
for severity of ADRs showed that 75% of the ADRs reported were mild and 
rest were moderate. This study also found that combination of sulphonylureas 
with biguanides was responsible for most of the ADRs and among all the 
ADRs reported hypoglycemia was the commonest followed by pruritis as the 
least common.  
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9. Summary: 
DM is a metabolic disorder with disastrous effect on major organ 
system if not treated appropriately. Drug utilization studies are designed to 
evaluate the use of different classes of drugs in a population both 
quantitatively and qualitatively. DM is an endocrine disorder which needs 
lifelong therapy. Adverse effect and pharmacoeconomics of drugs have a 
major impact on adherence to therapy.   
Hence this cross sectional study was done to study the prescription 
pattern, adverse effects and pharmacoeconomics of drugs used in the 
treatment of DM. 169 prescriptions were analyzed during the study period. 
Our study revealed that antidiabetic most frequently utilized was metformin 
which was in accordance with the guidelines.34 Utilization of newer drugs 
shows the importance of prescribing antidiabetic medication based on 
evidence based medicine among the treating physician. DM was treated 
frequently with combination of metformin and glimepiride.  
Adverse effect most commonly encountered during the study period 
was hypoglycemia. Majority of the ADRs were due to combination of 
antidiabetics. Majority of the reported ADRs were probable using WHO scale 
and possible using Naranjo scale. Most of the ADRs were not preventable as 
per modified Schumock and Thornton scale. It was concluded that all the 
ADRs were not severe as assessed by modified Hartwig and Siegel scale.       
Pharmacoeconomic evaluation showed a dramatic increase in the cost 
of monotherapy when prescribed using brand names compared to generic 
name of drugs.   
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Annexure CONSENT FORM PART 1OF 2 INFORMATION FOR PARTICIPANTS OF THE STUDY  Dear Volunteers,              We welcome you and thank you for your keen interest in participation in this research project. Before you participate in this study, it is important for you to understand why this research is being carried out. This form will provide you all the relevant details of this research. It will explain the nature, the purpose, the benefits, the risks, the discomforts, the precautions and the information about how this project will be carried out. It is important that you read and understand the contents of the form carefully. This form may contain certain scientific terms and hence, if you have any doubts or if you want more information, you are free to ask the study personnel or the contact person mentioned below before you give your consent and also at any time during the entire course of the project.        1. Name of the Principal Investigator     :  Dr.Shanthi.M Post Graduate (I yr) Department of Pharmacology SMIMS, Kulasekharam  2. Name of the Guide                                         :   Dr. Rema Menon. N  Professor and Head Department of Pharmacology SMIMS, Kulasekharam  3. Name of the Co-Guide                               :  (i) Dr. Kaniraj Peter. J Professor and Head Department of Medicine SMIMS, Kulasekharam  (ii) Dr. Madhavrao. C  Assistant Professor  Department of Pharmacology SMIMS, Kulasekharam           
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Annexure 4. Institute: Sree Mookambika Institute of Medical Sciences, Kulasekharam-629161, Kanyakumari district, Tamilnadu 5. Title of the study: A study of drug utilization pattern and adverse drug reaction profile of antidiabetic drugs in patients attending a teaching hospital   6. Background information: Prevalence of Diabetes mellitus is progressing rapidly worldwide.  Fourth leading cause of death is due to this non-communicable disease. Response to anti-diabetic drugs varies in different population. Drug utilization research establishes the current trend in the use of anti-diabetic drugs and adverse drug reaction including the new drug and to identify irrational prescription. Irrational  prescription  can  affect  the  adherence  to  drugs thereby  not reaching   therapeutic  goal  ultimately  rising  the economic burden. Since you are diagnosed to be diabetic and on treatment with anti diabetic drugs it is proposed to do the study to evaluate the drug utilization-pattern and adverse drug reactions of anti-diabetic drugs in the Medicine out-patient department of this institution.                                          7. Aims and objectives: To, assess the following in the outpatient department (OPD) of Medicine, Sree Mookambika Institute of Medical Sciences Kulasekharam (K.Kdistrict.TN)     i. The pattern of anti diabetic drugs prescription                           ii. Rationality of using anti diabetic drugs as mono therapy and combination therapy                                         iii. The prescription writing pattern by brand name and generic name                                     iv. The pharmacoeconomic of anti diabetic drugs prescribed for one month  v. To study adverse drug reaction profile of anti diabetic drugs prescribed                                                   8. Scientific justification of the study: Drug utilization research establish current trend in the use of anti diabetic drugs and adverse drug reactions including the new drug and to identify irrational prescription. Irrational prescription can affect the adherence to drugs thereby not reaching therapeutic goal ultimately rising the economic burden. Till date no study on drug utilization pattern and adverse drug reaction profile of anti diabetic drugs is conducted in this institution. Hence it has been proposed to conduct the study to evaluate the drug utilization pattern 
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Annexure and adverse drug reaction profile of anti diabetic drugs in the Medicine outpatient department of this institution.        9. Procedure for the study: The study will be carried out after getting informed written consent from each participant. The study will not have any impact on the treatment given by physician. Study will be carried out in collaboration with the Medicine department. Enrolled subject name, age, sex, co-morbid condition and treatment if any will be recorded in a predesigned case record form. Details of the prescribed anti diabetic drug(s) will be recorded. Conclusion of the study will be made from the details in the case record form.                    10. Expected risks for the participants: This study does not involve any risk to the participant                                                                                11. Expected benefits of research for the participants: This study does not provide any direct benefit to the participant, however the data obtained from the study will be useful for better medical health care in the future 12. Maintenance of confidentiality: Will be maintained                      13. Why have I been chosen to be in this study? You are diagnosed as diabetes mellitus (Type1/Type2) and prescribed with anti diabetic drugs, hence according to the inclusion and exclusion criteria you are recruited into this study. 14. How many people will be in the study? 157                                                                                         15.  Agreement of Compensation to the participants (In case of a study related injury): Not applicable                                                    16. Anticipated prorated payment, if any, to the participant(s) of the study: No  17. Can I withdraw from the study at any time during the study period? The study participant can withdraw from the study at any time and will not involve any penalty or loss of benefits to which the participant is otherwise entitled. 18. If there is any new findings / information, would I be informed? Yes     19. Expected duration of the Participant’s participation in the study: 1 day   20. Any other pertinent information: No      
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Annexure 21. Whom do I contact for further information?  For any study related queries, you are free to contact                                         Dr.Shanthi.M                     Post Graduate                       Department of Pharmacology                   SMIMS                            Mobile number: 9442406103                             Email:dr_shanthisenthil@yahoo.com   Place: Kulasekharam                             Signature of  the  Principal Investigator                                                                                                                                                                                                                                              Date :                                                                          Signature of the Participant             
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Annexure CONSENT FORM                                                         PART 2 OF 2      PARTICIPANTS CONSENT FORM         The details of the study have been explained to me in writing and the details have been fully explained to me. I am aware that the results of the study may not be directly beneficial to me but will help in the advancement of medical sciences. I confirm that I have understood the study and had the opportunity to ask questions. I understood that my participation in the study is voluntary and that I am free to withdraw at any time, without giving any reason, without the medical care that will normally be provided by the hospital being affected. I agree not to restrict the use of any data or results that arise from this study provided such a use is only for scientific purpose(s). I have been given an information sheet giving details of the study. I fully consent to participate in the study titled ‘A study of drug utilization pattern and adverse drug reaction profile of antidiabetic drugs in patients attending SMIMS’    Serial no/Reference no:          Name of the Participant:        Address of the Participant:                                                                                       Signature of the participant  Witnesses:          1.                                                             2. Date:                                                                                       Place: Kulasekharam                                                    
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Annexure                         SREE MOOKAMBIKA INSTITUTE OF MEDICAL SCIENCES                                       KULASEKHARAM                          Department of Pharmacology                                                                      Title of study: A Study of Drug Utilization Pattern and Adverse Drug Reaction Profile of Antidiabetic drugs in patients attending a teaching hospital                                                  Case Record Form               Serial No:    Medicine OPD Reference No:                                        Participant Name:                                                    Age:                            Sex:                                                                                      Address:             Ht:                          Wt:                                                               Diagnosis :          
                   * Route of administration                                                                                 
Sl.No Formulation Drug name  (as prescribed        by the physician)  
Dose Frequency  Duration ROA* Before or after food Generic name  Cost (Rs)/mth 
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Annexure Associated co-morbid condition(s):                        Concurrent drugs taken for other co-morbid conditions:                                  Adverse drug reactions reported by participants:                    (If adverse reaction experienced details will be filled up in CDSCO ADR form)           
         Place: Kulasekharam           Date:                                      Signature of the Principal Investigator                                                                                                                                                                                                                                                                                         
Adverse drug reaction  Experienced/Not experienced Hypoglycaemia  Nausea, Vomiting  Jaundice  Anaemia  Hypersensitivity reaction  Weight gain   Edema  Resistance  Lipoatrophy, Lipohypertrophy    Any other ADRs  
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Annexure 
  Abbreviations ADA :American Diabetes Association ADR :Adverse drug reaction AIIMS :All India institute of medical sciences AMPK :Adenosine 5’ monophosphate activated protein kinase BMI :Body mass index BPH :Benign prostatic hypertrophy CDA :Canadian Diabetes Association  CDSCO :Central drugs standard control organization COPD :Chronic obstructive pulmonary disease CSII :Continuous subcutaneous insulin infusion DM :Diabetes mellitus DPP-4 :Dipeptidyl peptidase 4 inhibitors DUR :Drug utilization research DUS :Drug utilization study ESRD :End stage renal disease FBPase :Fructose 1,6 bisphosphatase GIP :Glucose dependent insulinotropic polypeptide GLP-1 :Glucagon like polypeptide 1 GLUT :Glucose transporter GSK-3 :Glycogen synthase kinase 3 HbA1C :Glycosylated haemoglobin HLA :Human leucocyte antigen HNF :Hepatocyte nuclear transcription factor IAP :Islet amyloid peptide IgE  :Immunoglobulin E 
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Annexure IHEC :Institutional Human Ethics Committee INR :Indian rupee IPF :Insulin promoter factor IRS :Insulin receptor substrate KATP :Adenosine 5’ triphosphate sensitive potassium channel MODY :Maturity onset diabetes of young MDI :Multiple dose insulin NPH :Neutral protamine Hagedorn OHA :Oral hypoglycemic agent OPD :Out-patient department PCOS :Polycystic ovarian syndrome PDRM :Preventable drug related morbidity PPAR :Peroxisome proliferator activated receptor PPRE :Peroxisome proliferator activated  receptor response element PvPI :Pharmacovigilance programme of India RXR :Retinoid X receptor SGLT-2 :Sodium glucose co-transport 2 SUR :Sulphonylurea receptor TNF α :Tumour necrosis factor α UMC :Uppsala monitoring centre WHO :World health organisation 
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